Document and Entity Information
Document and Entity Information | 9 Months Ended |
Sep. 30, 2017 | |
Document And Entity Information | |
Entity Registrant Name | Renovacare, Inc. |
Entity Central Index Key | 1,016,708 |
Document Type | S1 |
Document Period End Date | Sep. 30, 2017 |
Amendment Flag | false |
Current Fiscal Year End Date | --12-31 |
Is Entity a Well-known Seasoned Issuer? | No |
Is Entity a Voluntary Filer? | No |
Is Entity's Reporting Status Current? | Yes |
Entity Filer Category | Smaller Reporting Company |
Document Fiscal Year Focus | 2,017 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) | Sep. 30, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Current assets | |||
Cash and cash equivalents | $ 1,149,604 | $ 418,031 | $ 397,589 |
Prepaid expenses | 11,800 | 31,535 | 10,293 |
Total current assets | 1,161,404 | 449,566 | 407,882 |
Equipment, net of accumulated depreciation of $291 and $53, respectively | 661 | 898 | |
Intangible assets | 152,854 | 152,854 | 152,854 |
Total assets | 1,314,919 | 603,318 | 560,736 |
Current liabilities | |||
Accounts payable | 101,911 | 71,563 | |
Accounts payable - related parties | 20,000 | 33,290 | 30,095 |
Contract payable | 100,000 | 150,000 | 134,125 |
Interest payable to related parties | 71,185 | 15,220 | |
Convertible promissory notes payable to related parties, net of discount of $302,728 and $534,519, respectively | 817,272 | 165,481 | |
Total current liabilities | 1,110,368 | 363,991 | 235,783 |
Contract and contribution payable, less current portion | 100,000 | ||
Total liabilities | 1,110,368 | 363,991 | 335,783 |
Commitments and contingencies | |||
Stockholders' equity | |||
Preferred stock: $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding | |||
Common stock: $0.00001 par value; 500,000,000 shares authorized, 75,225,418 and 70,069,693 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively | 753 | 702 | 678 |
Additional paid-in capital | 13,949,028 | 11,290,209 | 9,197,970 |
Retained deficit | (13,745,230) | (11,051,584) | (8,973,695) |
Total stockholders' equity | 204,551 | 239,327 | 224,953 |
Total liabilities and stockholders' equity | $ 1,314,919 | $ 603,318 | $ 560,736 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) | Sep. 30, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Current assets | |||
Accumulated depreciation | $ 291 | $ 53 | |
Current liabilities | |||
Net of discount on related party | $ 302,728 | $ 534,519 | |
Stockholders' equity | |||
Preferred stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 |
Preferred stock, Authorized | 10,000,000 | 10,000,000 | 10,000,000 |
Preferred stock, shares Issued | 0 | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 | 0 |
Common stock, par value | $ 0.00001 | $ 0.00001 | $ 0.00001 |
Common stock, Authorized | 500,000,000 | 500,000,000 | 500,000,000 |
Common stock, shares Issued | 75,225,418 | 70,069,693 | 67,781,934 |
Common stock, shares outstanding | 75,225,418 | 70,069,693 | 67,781,934 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016 | Dec. 31, 2015 | |
Consolidated Statements Of Operations | ||||||
Revenue | ||||||
Operating expense | ||||||
Research and development | 139,819 | 45,381 | 363,785 | 231,013 | 309,503 | 281,218 |
General and administrative | 434,923 | 223,832 | 1,599,338 | 1,347,063 | 1,588,719 | 1,037,289 |
Total operating expense | 574,742 | 269,213 | 1,963,123 | 1,578,076 | 1,898,222 | 1,318,507 |
Loss from operations | (574,742) | (269,213) | (1,963,123) | (1,578,076) | (1,898,222) | (1,318,507) |
Other income (expense) | ||||||
Interest income | 738 | 149 | 1,195 | 768 | 1,034 | |
Interest expense | (20,775) | (2,819) | (56,641) | (2,819) | 15,220 | |
Accretion of debt discount | (256,667) | (30,753) | (675,077) | (30,753) | (165,481) | |
Total other income (expense) | (276,704) | (33,423) | (730,523) | (32,804) | (179,667) | |
Net loss | $ (851,446) | $ (302,636) | $ (2,693,646) | $ (1,610,880) | $ (2,077,889) | $ (1,318,507) |
Basic and Diluted Loss per Common Share | $ (0.01) | $ 0 | $ (0.04) | $ (0.02) | $ (0.03) | $ (0.02) |
Weighted average number of common shares outstanding - basic and diluted | 75,123,280 | 69,955,847 | 73,837,107 | 69,695,772 | 69,772,485 | 67,233,254 |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($) | Common Stock | Additional Paid-In Capital | Retained Deficit | Total |
Beginning Balance, Shares at Jan. 01, 2015 | 66,575,122 | |||
Beginning Balance, Amount at Jan. 01, 2015 | $ 666 | $ 8,128,860 | $ (7,655,188) | $ 474,338 |
Issuance of common stock plus warrants,Shares | 1,010,000 | |||
Issuance of common stock plus warrants, Amount | $ 10 | 1,009,990 | 1,010,000 | |
Issuance of common stock from the exercise of warrants, Shares | 196,812 | |||
Issuance of common stock from the exercise of warrants, Amount | $ 2 | (2) | ||
Stock based compensation due to common stock purchase options | 59,122 | 59,122 | ||
Net loss | (1,318,507) | (1,318,507) | ||
Ending Balance, Shares at Dec. 31, 2015 | 67,781,934 | |||
Ending Balance, Amount at Dec. 31, 2015 | $ 678 | 9,197,970 | (8,973,695) | 224,953 |
Issuance of common stock from the exercise of warrants, Shares | 2,273,913 | |||
Issuance of common stock from the exercise of warrants, Amount | $ 24 | 1,109,977 | 1,110,001 | |
Issuance of common stock from the exercise of stock options, Shares | 13,846 | |||
Issuance of common stock from the exercise of stock options, Amount | ||||
Stock based compensation due to common stock purchase options | 296,123 | 296,123 | ||
Reversal of stock based compensation due to forfeiture of stock options | (13,861) | (13,861) | ||
Discount on convertible promissory note due to detachable warrants | 340,735 | 340,735 | ||
Discount on convertible promissory note due to beneficial conversion feature | 359,265 | 359,265 | ||
Net loss | (2,077,889) | (2,077,889) | ||
Ending Balance, Shares at Dec. 31, 2016 | 70,069,693 | |||
Ending Balance, Amount at Dec. 31, 2016 | $ 702 | 11,290,209 | (11,051,584) | 239,327 |
Issuance of common stock from the exercise of warrants, Shares | 4,592,895 | |||
Issuance of common stock from the exercise of warrants, Amount | $ 46 | 344,578 | 344,624 | |
Issuance of common stock from the exercise of stock options, Shares | 102,580 | |||
Issuance of common stock from the exercise of stock options, Amount | $ 1 | (1) | ||
July 2017 Private Placement units issued, Shares | 460,250 | |||
July 2017 Private Placement units issued, Amount | $ 4 | 1,122,606 | 1,122,610 | |
Stock based compensation due to common stock purchase options | 748,350 | 748,350 | ||
Discount on convertible promissory note due to detachable warrants and beneficial conversion feature | 443,286 | 443,286 | ||
Net loss | (2,693,646) | (2,693,646) | ||
Ending Balance, Shares at Sep. 30, 2017 | 75,225,418 | |||
Ending Balance, Amount at Sep. 30, 2017 | $ 753 | $ 13,949,028 | $ (13,745,230) | $ 204,551 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016 | Dec. 31, 2015 | |
Cash flows from operating activities | ||||
Net loss | $ (2,693,646) | $ (1,610,880) | $ (2,077,889) | $ (1,318,507) |
Adjustments to reconcile net loss to net cash flows from operating activities | ||||
Depreciation | 237 | 53 | ||
Impairment loss | 10,000 | |||
Stock based compensation expense | 748,350 | 287,238 | 282,262 | 59,122 |
Accretion of debt discount | 675,077 | 30,753 | 165,481 | |
Changes in operating assets and liabilities: | ||||
Decrease (increase) in prepaid expenses | 19,735 | (1,737) | (21,242) | (2,845) |
Increase (decrease) in accounts payable | 101,911 | (43,407) | (71,563) | 65,381 |
Increase (decrease) in accounts payable - related parties | (13,290) | 9,497 | 3,195 | 22,840 |
Increase (decrease) in interest payable - related parties | 55,965 | 2,819 | 15,220 | |
Increase (decrease) in contract payable | (50,000) | (84,125) | (84,125) | (131,500) |
Net cash flows from operating activities | (1,155,661) | (1,409,842) | (1,788,608) | (1,295,509) |
Cash flows from investing activity | ||||
Purchase of equipment | (951) | |||
Net cash flows from investing activity | (951) | |||
Cash flows from financing activities | ||||
Proceeds from exercise of warrants and issuance of common stock | 1,467,234 | 1,000,000 | 1,110,001 | 1,010,000 |
Proceeds from the issuance of convertible promissory notes | 445,000 | 700,000 | 700,000 | |
Payments of convertible promissory notes | (25,000) | |||
Net cash flows from financing activities | 1,887,234 | 1,700,000 | 1,810,001 | 1,010,000 |
Increase in cash and cash equivalents | 731,573 | 290,158 | 20,442 | (285,509) |
Cash and cash equivalents at beginning of period | 418,031 | 397,589 | 397,589 | 683,098 |
Cash and cash equivalents at end of period | 1,149,604 | 687,747 | 418,031 | 397,589 |
Supplemental disclosure of cash flow information: | ||||
Interest paid in cash | 676 | |||
Income taxes paid in cash | ||||
Supplemental disclosure of non-cash transactions: | ||||
Discount on convertible promissory note due to detachable warrants and beneficial conversion feature | $ 443,286 | $ 700,000 | ||
Debt discount recorded for value of warrants issued | 340,735 | |||
Debt discount recorded for beneficial conversion feature | $ 359,265 |
Organization, Nature and Contin
Organization, Nature and Continuance of Operations | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Notes to Financial Statements | ||
Note 1. Organization, Nature and Continuance of Operations | Basis of Presentation The unaudited financial statements of RenovaCare, Inc. (the Company) as of September 30, 2017, and for the three and nine months ended September 30, 2017 and 2016, have been prepared in accordance with generally accepted accounting principles (GAAP) in the United States for interim financial reporting and include the Companys wholly-owned subsidiary, RenovaCare Sciences. Accordingly, they do not include all of the disclosures required by accounting principles generally accepted in the United States for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016, as filed with the Securities and Exchange Commission as part of the Companys Form 10-K. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the interim financial information have been included. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year. Organization RenovaCare, Inc., together with its wholly owned subsidiary, focuses on the acquisition, research, development and, if warranted, commercialization of autologous (using a patient's own cells) cellular therapies that can be used for medical and aesthetic applications. On July 12, 2013, the Company, through its wholly owned subsidiary, RenovaCare Sciences Corp., completed the acquisition of its flagship technologies (collectively, the CellMist TM The CellMist TM CellMist TM SkinGun TM TM TM Going Concern The Company's activities have consisted principally of performing research and development activities and raising capital. These activities are subject to significant risks and uncertainties, including possible failure of preclinical testing and failing to secure additional funding before achieving sustainable revenue and profit from operations. The Company's ability to fund the development of its cellular therapies will depend on the amount and timing of cash receipts from future financing activities. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Companys ability to establish itself as a profitable business. The Company does not have any commercialized products, has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies. Over the past year, the Company has been funded through the sale of equity securities and proceeds from convertible promissory notes. As of September 30, 2017, the Company had approximately $1,149,604 of cash. On October 16, 2017, the Company completed a private placement with a group of private investors, whereby the Company received $2,300,000 from the sale of common stock and warrants. The Company believes that, as a result, it currently has sufficient cash to meet its funding requirements over the next year. However, the Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it will need to raise additional capital to accomplish its business plan. The Company expects to seek to obtain additional funding through the sale of its securities. There can be no assurance as to the availability or terms upon which such financing and capital might be available. Recent Accounting Pronouncements Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification. In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09, Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting (Topic 718), which is intended to simplify several aspects of the accounting for share-based payment award transactions. The guidance was effective for annual periods beginning after December 31, 2016, with early adoption permitted. The Company adopted the guidance with no material impact on its financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes ASC Topic 840, Leases, and creates a new topic, ASC Topic 842, Leases. ASU 2016-02 requires lessees to recognize a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months on its balance sheet. ASU 2016-02 also expands the required quantitative and qualitative disclosures surrounding leases. ASU 2016-02 is effective for the Company beginning January 1, 2019. Early adoption is permitted. The Company has determined that the adoption of ASU 2016-02 will currently have no impact on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes (ASU 2015-17). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. The guidance was effective for annual periods beginning after December 31, 2016, with early adoption permitted. The Company adopted the guidance with no material impact on its consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017, and early adoption is permitted. The Company has determined that the adoption of ASU 2014-09 will currently have no impact on its consolidated financial statements. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Companys previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion other than as discussed above. The Company believes that none of the new standards will have a significant impact on the financial statements. Earnings (Loss) Per Share The Company presents both basic and diluted earnings per share (EPS) amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive. Following is the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2017 and 2016: Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (851,446 ) $ (302,636 ) $ (2,693,646 ) $ (1,610,880 ) Denominator: Weighted average number of common shares outstanding 75,123,280 69,955,847 73,837,107 69,695,772 Basic and diluted EPS $ (0.01 ) $ (0.00 ) $ (0.04 ) $ (0.02 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 545,000 445,000 545,000 445,000 Warrants 2,689,158 7,380,503 2,689,158 7,380,503 Convertible debt 647,813 623,067 647,813 623,067 Total shares not included in the computation of diluted losses per share 3,881,971 8,448,570 3,881,971 8,448,570 | RenovaCare, Inc., together with its wholly owned subsidiary (the "Company"), focuses on the acquisition, research, development and, if warranted, commercialization of autologous (using a patient's own cells) cellular therapies that can be used for medical and aesthetic applications. On July 12, 2013, the Company, through its wholly owned subsidiary, RenovaCare Sciences Corp. (RenovaCare Sciences), completed the acquisition of its flagship technologies (collectively, the CellMist TM TM TM TM The Company has recently incurred net operating losses and operating cash flow deficits. As of December 31, 2016, the Companys accumulated deficit is $11,051,584. The Company does not currently generate revenues and will continue to incur losses from operations and operating cash flow deficits in the future. Subsequent to December 31, 2016, the Company received $445,000 upon the sale of three convertible promissory notes. Management believes that the Company's cash and cash equivalent balances and other external sources of capital will be sufficient to meet the Company's cash requirements through June 2017. The Company's activities are subject to significant risks and uncertainties due to the stage of the development of the Company's cellular therapies. The future of the Company after June 2017 will depend on its ability to successfully raise capital from external sources to fund operations. If the Company is unable to obtain adequate funds, or if such funds are not available to it on acceptable terms, the Company's ability to continue its business to develop its cellular therapies will be significantly impaired and it may cause the Company to curtail operations. The matters described above raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements were issued. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern. |
Significant Accounting Policies
Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Note 2. Significant Accounting Policies | Principles of Consolidation These consolidated financial statements have been prepared in accordance with US GAAP and include the accounts of the Company and its wholly owned subsidiary, RenovaCare Sciences. All significant intercompany transactions and balances have been eliminated. RenovaCare Sciences was incorporated under the laws of the State of Nevada on June 12, 2013. Applicable Accounting Guidance Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification. In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09, Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting (Topic 718), which is intended to simplify several aspects of the accounting for share-based payment award transactions. The guidance will be effective for the fiscal year beginning after December 15, 2016, including interim periods within that year. The Company does not expect adoption of ASU 2016-09 to have a material impact on its financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes ASC Topic 840, Leases, and creates a new topic, ASC Topic 842, Leases. ASU 2016-02 requires lessees to recognize a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months on its balance sheet. ASU 2016-02 also expands the required quantitative and qualitative disclosures surrounding leases. ASU 2016-02 is effective for the Company beginning January 1, 2019. Early adoption is permitted. The Company has determined that the adoption of ASU 2016-02 will currently have no impact on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes (ASU 2015-17). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. ASU 2015-17 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Early adoption is permitted and the standard may be applied either retrospectively or on a prospective basis to all deferred tax assets and liabilities. The Company has determined that the adoption of ASU 2015-17 will currently have no impact on its consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017, and early adoption is permitted. The Company has determined that the adoption of ASU 2014-09 will currently have no impact on its consolidated financial statements. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Companys previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion other than as discussed above. The Company believes that none of the new standards will have a significant impact on the financial statements. Accounting Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results, as determined by future events, may differ from these estimates. Cash and Cash Equivalents The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents may at times exceed federally insured limits. Fair Value Measurement The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1. Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. The Company has no assets or liabilities valued with Level 1 inputs. Level 2. Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. The Company has no assets or liabilities valued with Level 2 inputs. Level 3. Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company has no assets or liabilities valued with Level 3 inputs. Fair Value of Financial Instruments The carrying value of cash and cash equivalents, accounts payable, and contract and contribution payable, approximate their fair value because of the short-term nature of these instruments and their liquidity. It is not practical to determine the fair value of the Companys note payable and accrued interest due to the complex terms. Management is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments. Research and Development Costs The Company intends to outsource its research and development efforts and expense related costs as incurred, including the cost of manufacturing product for testing, licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and other intellectual property acquired will be capitalized as it relates to particular research and development projects that may have alternative future uses. Equipment Equipment is carried at cost, less accumulated depreciation and amortization. Major improvements are capitalized, while repair and maintenance are expensed when incurred. Renewals and betterments that materially extend the life of the assets are capitalized. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in income for the period. Depreciation is computed on a straight-line basis over estimated useful lives of the related assets. The estimated useful lives of depreciable assets are: Estimated Useful Lives Office equipment 3-5 years Furniture & equipment 5-7 years Intangible Assets The Companys intangible asset consists primarily of the CellMist TM The Company assessed the following qualitative factors that could affect any change in the fair value of the intangible asset: analysis of the technology's current phase, additional testing necessary to bring the technology to market, development of competing products, changes in projections caused by delays, changes in regulations, changes in the market for the technology and changes in cost projections to bring the technology to market. Based on a qualitative assessment, management concluded that a positive assertion can be made from the qualitative assessment that it is more likely than not that the intangible asset related to the CellMist TM Stock Options The Company measures all stock-based compensation awards using a fair value method on the date of grant and recognizes such expense in its consolidated financial statements over the requisite service period. The Company uses the Black-Scholes pricing model to determine the fair value of stock-based compensation awards on the date of grant. The Black-Scholes pricing model requires management to make assumptions regarding option lives, expected volatility, and risk free interest rates. The Companys policy is to issue new shares upon exercise of options. Income Taxes The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively. Earnings (Loss) Per Share The Company presents both basic and diluted earnings per share ("EPS") amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive. Following is the computation of basic and diluted net loss per share for the years ended December 31, 2016 and 2015: Years Ended December 31, 2016 2015 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (2,077,889 ) $ (1,318,507 ) Denominator: Weighted average number of common shares outstanding 69,772,485 67,233,254 Basic and diluted EPS $ (0.03 ) $ (0.02 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 385,000 257,500 Warrants 7,280,503 8,970,000 Convertible debt 464,428 - Total shares not included in the computation of diluted losses per share 8,129,931 9,227,500 Related Party Transactions A related party is generally defined as (i) any person who holds 10% or more of the Company's securities and their immediate families; (ii) the Company's management; (iii) someone who directly or indirectly controls, is controlled by or is under common control with the Company; or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. See Note 9. Related Party Transactions, for further discussion. |
Assets - Intellectual Property
Assets - Intellectual Property | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Notes to Financial Statements | ||
Note 2. Assets - Intellectual Property | On July 12, 2013, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an asset purchase agreement (APA) with Dr. Jörg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlachs rights, title and interest in the CellMist TM | On July 12, 2013, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an asset purchase agreement (APA) with Dr. Jörg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlachs rights, title and interest in the CellMist TM |
Contract Payable
Contract Payable | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Notes to Financial Statements | ||
Note 3. Contract Payable | On June 9, 2014, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an amended asset purchase agreement (the Amended APA) with Dr. Jörg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlach's rights, title and interest in the CellMist System. The Amended APA provided for cash payments of $300,000 as partial consideration for the purchase which are payable as follows: (a) $100,000 on December 31, 2014; (b) $50,000 on December 31, 2015; (c) $50,000 on December 31, 2016; and (d) $100,000 on December 31, 2017. At September 30, 2017, $100,000 of the amount payable to Dr. Gerlach was recorded as current liabilities in the accompanying consolidated balance sheet. | On May 1, 2015, the Company entered into an option agreement (the Option Agreement) with Dr. Gerlach, pursuant to which the Company obtained a one-year exclusive option to evaluate a wound cap technology (the Technology). Pursuant to the terms of the Option Agreement, the Company paid Dr. Gerlach a non-refundable fee of $24,000 in four quarterly installments of $6,000, with the first installment paid in May 2015 and the final payment made during the three months ended March 31, 2016. On September 25, 2014, the Company entered into a Charitable Grant Agreement with the University of Pittsburgh (the "University"), pursuant to which the Company committed to provide a charitable donation to the University in the aggregate amount of $75,000 (the "Grant"). The Company paid the Grant in eight quarterly installments of $9,375, with the first payment made in October 2014 and the final payment made in July 2016. Dr. Gerlach, from whom the Company purchased the CellMist System, is a professor at the University. On June 9, 2014, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an amended asset purchase agreement (the Amended APA) with Dr. Jörg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlach's rights, title and interest in the CellMist System. The Amended APA provided for cash payments of $300,000 as partial consideration for the purchase which are payable as follows: (a) $100,000 on December 31, 2014; (b) $50,000 on December 31, 2015; (c) $50,000 on December 31, 2016; and (d) $100,000 on December 31, 2017. At December 31, 2016, $150,000 of the amount payable to Dr. Gerlach was recorded as current liabilities in the accompanying consolidated balance sheet. Below is a summary of contract and contribution payable at December 31, 2016 and 2015: 2016 2015 Contribution payable to the University of Pittsburgh, in quarterly installments of $9,375, through July 2016 $ - $ 28,125 Contract payable to Dr. Jorg Gerlach in connection with the APA. $50,000 was due on December 31, 2016 and $100,000 is due on December 31, 2017 150,000 200,000 Contract for option agreement purchase - 6,000 Total 150,000 234,125 Less: current portion (150,000 ) (134,125 ) Long-term portion $ - $ 100,000 See also Note 9. Related Party Transactions. |
Debt
Debt | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Notes to Financial Statements | ||
Note 4. Debt | September 9, 2016, $700,000 Convertible Promissory Note On September 9, 2016, the Company entered into a loan agreement (the Loan Agreement KCC Note Per the Loan Agreement, the Company issued KCC a Series E Stock Purchase Warrant (the Series E Warrant The Loan Agreement provides KCC with registration rights for all of the shares issuable upon conversion of the Note, including conversion of the note issued for the remaining $200,000, if applicable, and exercise of the Series E Warrant, beginning on the first anniversary of the Loan Agreement. The Company calculated the debt discount related to the Note and Series E Warrant by first allocating the respective fair value of the Note and Series E Warrant based upon their relative fair values to the total Note proceeds. The fair value of the Series E Warrant issued with the Note was calculated using the Black-Scholes option pricing model and the following assumptions: exercise price - $1.25 per share; market price of common stock - $1.54 per share; estimated volatility 92.3%; risk free interest rate - 1.23%; expected dividend rate - 0% and expected life - 5.0 years. The resulting fair value of $340,735 was allocated to the Series E Warrant. The intrinsic value of the beneficial conversion feature amounted to $359,265. The resulting $700,000 discount to the Note is being accreted over the 1.25 year term of the Note. During the three and nine months ended September 30, 2017, the Company recognized $13,051 and $38,093 of interest expense and $134,728 and $399,791 of accretion related to the debt discount. The remaining debt discount of $134,728 will be amortized over the next quarter through December 31, 2017. February 2017, $445,000 Convertible Promissory Notes Between February 23, 2017 and March 9, 2017, the Company entered into three separate loan agreements containing identical terms (the February 2017 Loan Agreements Sierchio Investor Holders February 2017 Notes Per the February 2017 Loan Agreement, the Company issued Sierchio, the Investor and KCC a Series F Stock Purchase Warrant (the Series F Warrant The February 2017 Loan Agreements provide the Holders with registration rights for all of the shares issuable upon conversion of the February 2017 Notes, including exercise of the Series F Warrants, beginning on the first anniversary of the February 2017 Loan Agreements. On July 27, 2017, the Company repaid the Investor in full, including $25,000 of note principal and $676 of accrued interest. During the three and nine months ended September 30, 2017, the Company recognized $7,724 and $18,548 of interest expense and $121,939 and $275,286 of accretion related to the debt discount. The remaining debt discount of $168,000 will be amortized over the next two quarters through March 31, 2018. | On September 9, 2016, the Company entered into a loan agreement (the Loan Agreement) with Kalen Capital Corporation (KCC); KCC is wholly owned by Mr. Harmel S. Rayat, the Company's majority shareholder. Pursuant to the terms of the Loan Agreement, KCC agreed to loan the Company up to $900,000 at an annual interest rate of 7% per year, compounded quarterly. KCC provided the Company with an initial loan in the amount of $700,000, which was evidenced by a convertible promissory note (the Note); the remaining $200,000 may be loaned prior to December 31, 2017, upon the mutual agreement of the Company and KCC. The Note, including any interest due thereon, may be prepaid at any time without penalty. The Note matures on December 31, 2017, and, beginning on the first anniversary of the Note, can be converted, at KCCs sole discretion, into shares of the Companys common stock at conversion rate equal to the lesser of: (i) $1.54, or the closing price of the Companys common stock on the day prior to the issuance of the Note or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which KCC elects to convert the Note. Per the Loan Agreement, the Company issued KCC a Series E Stock Purchase Warrant (the Series E Warrant) to purchase up to 584,416 shares of the Companys common stock at a purchase price of the lesser of: (i) $1.54, the closing price of the Companys common stock on the day prior to issuance of the Series E Warrant; or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant. The Series E Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis. The Loan Agreement provides KCC with registration rights for all of the shares issuable upon conversion of the Note, including conversion of the note issued for the remaining $200,000, if applicable, and exercise of the Series E Warrant, beginning on the first anniversary of the Loan Agreement. The Company calculated the debt discount related to the Note and Series E Warrant by first allocating the respective fair value of the Note and Series E Warrant based upon their relative fair values to the total Note proceeds. The fair value of the Series E Warrant issued with the Note was calculated using the Black-Scholes option pricing model and the following assumptions: exercise price - $1.25 per share; market price of common stock - $1.54 per share; estimated volatility 92.3%; risk free interest rate - 1.23%; expected dividend rate - 0% and expected life - 5.0 years. The resulting fair value of $340,735 was allocated to the Series E Warrant. The intrinsic value of the beneficial conversion feature amounted to $359,265. The resulting $700,000 discount to the Note is being accreted over the 1.25 year term of the Note. During the year ended December 31, 2016, the Company recognized $15,220 of interest expense and $165,481 of accretion related to the debt discount. The remaining debt discount of $534,519 will be amortized over the next four quarters through December 31, 2017. |
Common Stock and Warrants
Common Stock and Warrants | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Notes to Financial Statements | ||
Note 5. Common Stock and Warrants | Common Stock At June 30, 2017, the Company had 500,000,000 authorized shares of common stock with a par value of $0.00001 per share, 75,225,418 shares of common stock outstanding and 19,338,572 shares reserved for issuance under the Companys 2013 Long-Term Incentive Plan (the 2013 Plan) as adopted and approved by the Companys Board of Directors (the Board) on June 20, 2013 that provides for the grant of stock options to employees, directors, officers and consultants (See Note 6. Stock Options). During the nine months ended September 30, 2017, the Company had the following common stock related transactions: · On July 21, 2017, the Company completed a self-directed offering of 460,250 units of the Company's equity securities (the "Units") at a price of $2.44 per unit for $1,122,610 in aggregate proceeds (the July 2017 Private Placement Series G Warrants · On June 28, 2017, KCC exercised 114,493 Series F Warrants for $3.01 per share resulting in the issuance of 114,493 shares of common stock and proceeds of $344,624. · March 1, 2017, KCC exercised 1,326,087 Series B Warrants and 3,500,000 Series C Warrants, on a cashless basis, resulting in the issuance of 4,273,831 shares of common stock. · On February 17, 2017, Thomas Bold, the Companys President, CEO and Interim Chief Financial Officer exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 34,296 shares of common stock. · On February 10, 2017, Joseph Sierchio, a member of the Companys board of directors, exercised options to purchase up to 70,000 shares, on a cashless basis, resulting in the issuance of 38,642 shares of common stock. · On February 2, 2017, Kenneth Kirkland, a member of the Companys board of directors, exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 29,642 shares of common stock. · On January 10, 2017, Dr. Gerlach exercised a Series A Warrant to purchase up to 240,000 shares, on a cashless basis, resulting in the issuance of 204,571 shares of common stock. During the year ended December 31, 2016, the Company had the following common stock related transactions: · issued 100,000 shares of common stock, upon the exercise of a Series D Warrant at an exercise price of $1.10 per share resulting in $110,001 of proceeds to the Company. · issued 2,173,913 shares of common stock to KCC on February 2, 2016, upon the exercise of a portion of its Series B Warrant at an exercise price of $0.46 per share resulting in $1,000,000 of proceeds to the Company. · issued 13,846 shares of common stock upon the cashless exercise of an option to purchase 20,000 shares by Joseph Sierchio, a director. Warrants The following table summarizes information about warrants outstanding at September 30, 2017 and December 31, 2016: Shares of Common Stock Issuable from Warrants Outstanding as of Weighted Average September 30, December 31, Exercise Description 2017 2016 Price Expiration Series A 720,000 960,000 $ 0.35 July 12, 2019 Series B - 1,326,087 $ 0.46 November 29, 2018 Series C - 3,500,000 $ 0.49 November 29, 2018 Series D 910,000 910,000 $ 1.10 June 5, 2020 Series E 584,416 584,416 $ 1.54 September 8, 2021 Series F 14,492 - $ 3.45 February 23, 2022 & March 9, 2022 Series G 460,250 - $ 2.68 July 21, 2022 Total 2,689,158 7,280,503 As consideration for the CellMist TM A Series B Warrant with an exercise price of $0.46 to purchase 3,500,000 shares of common stock was issued on November 29, 2013 to KCC in connection with the 11/29 Financing. On February 2, 2016, KCC exercised a portion of its Series B Warrant for 2,173,913 shares of the Companys common stock resulting in proceeds of $1,000,000. On March 1, 2017, KCC exercised, in full, on a cashless basis, the remaining 1,326,087 Series B Warrants resulting in the issuance of 1,181,194 shares of common stock. A Series C Warrant with an exercise price of $0.49, to purchase 3,500,000 shares of common stock was issued on November 29, 2013 to KCC in connection with a financing. On March 1, 2017, KCC exercised, in full, on a cashless basis, the 3,500,000 Series C Warrants resulting in the issuance of 3,092,637 shares of common stock. Series D Warrants with an exercise price of $1.10 to purchase 1,010,000 shares of common stock were issued on June 5, 2015 in connection with the sale of units pursuant to a private placement. On December 6, 2016, a Series D Warrant to purchase shares was exercised resulting in the Company receiving $110,000 of proceeds. A Series E Warrant to purchase 584,416 shares of common stock was issued on September 9, 2016 in connection with the Loan Agreement. The Series E Warrant has an exercise price of the lesser of: (i) $1.54, the closing price of the Companys common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Companys common stock as quoted on the OTCQB for the five days prior to the date on which KCC elects to exercise the Warrant. The Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis using the formula contained therein. Three Series F Warrants to purchase 128,985 shares of common stock were issued between February 22, 2017 and March 9, 2017 in connection with the February 2017 Loan Agreements. The Series F Warrants have an exercise price of the lesser of: (i) $3.45, the closing price of the Companys common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Companys common stock as quoted on the OTCQB for the five days prior to the date on which the holder elects to exercise the Warrant. The Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis using the formula contained therein. On June 28, 2017, KCC exercised 114,493 Series F Warrants for $3.01 per share resulting in the issuance of 114,493 shares of common stock and proceeds of $344,624. The Series G Warrants to purchase 460,250 shares of common stock were issued on July 21, 2017 in connection with the sale of units pursuant to the July 2017 Private Placement. The Series G Warrants have an exercise price of $2.68, are exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis using the formula contained therein. | Common Stock At December 31, 2016, the Company had 500,000,000 authorized shares of common stock with a par value of $0.00001 per share, 70,069,693 shares of common stock outstanding and 19,595,000 shares reserved for issuance under the Companys 2013 Long-Term Incentive Plan (the 2013 Plan) as adopted and approved by the Companys Board of Directors (the Board) on June 20, 2013 that provides for the grant of stock options to employees, directors, officers and consultants (See Note 7. Stock Options). During the year ended December 31, 2016, the Company had the following common stock related transactions: · issued 100,000 shares of common stock, upon the exercise of a Series D Warrant at an exercise price of $1.10 per share resulting in $110,001 of proceeds to the Company. · issued 2,173,913 shares of common stock to KCC on February 2, 2016, upon the exercise of a portion of its Series B Warrant at an exercise price of $0.46 per share resulting in $1,000,000 of proceeds to the Company. · issued 13,846 shares of common stock upon the cashless exercise of an option to purchase 20,000 shares by Joseph Sierchio, a director. During the year ended December 31, 2015, the Company had the following common stock related transactions: · issued 196,812 shares of common stock upon the cashless exercise of a Series A Warrant to purchase up to 240,000 shares by Dr. Gerlach. · issued 1,010,000 shares of common stock On June 5, 2015, pursuant to a private placement with five investors for the purchase and sale of an aggregate of 1,010,000 units of equity securities (the Units) at a price of $1.00 per Unit for total gross proceeds of $1,010,000. Each Unit consisted of one share of common stock and one Series D Stock Purchase Warrant allowing the holder to purchase one share of the Companys common stock at a price of $1.10 per share for a period of five years; the Series D Warrants contain a provision allowing the holder to exercise the Series D Warrant on a cashless basis as further set forth therein. Warrants The following table summarizes information about warrants outstanding at December 31, 2016 and 2015: Shares of Common Stock Issuable from Warrants Outstanding as of Weighted December 31, Average Description 2016 2015 Exercise Price Expiration Series A 960,000 960,000 $ 0.35 July 12, 2019 Series B 1,326,087 3,500,000 $ 0.46 November 29, 2018 Series C 3,500,000 3,500,000 $ 0.49 November 29, 2018 Series D 910,000 1,010,000 $ 1.10 June 5, 2020 Series E 584,416 - $ 1.13 September 8, 2021 Total 7,280,503 8,970,000 As consideration for the CellMist TM A Series B Warrant with an exercise price of $0.46 to purchase 3,500,000 shares of common stock was issued on November 29, 2013 to KCC in connection with the 11/29 Financing. On February 2, 2016, KCC exercised a portion of its Series B Warrant for 2,173,913 shares of the Companys common stock resulting in proceeds of $1,000,000. A Series C Warrant with an exercise price of $0.49, to purchase 3,500,000 shares of common stock was issued on November 29, 2013 to KCC in connection with a financing. A Series D Warrant, with an exercise price of $1.10, to purchase 1,010,000 shares of common stock was issued on June 5, 2015 in connection with the sale of units pursuant to a private placement. On December 6, 2016, 100,000 Series D Warrants were exercised resulting in the Company receiving $110,000 of proceeds. A Series E Warrant to purchase 584,416 shares of common stock was issued on September 9, 2016 in connection with the Loan Agreement. The Series E Warrant has an exercise price of the lesser of: (i) $1.54, the closing price of the Companys common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Companys common stock as quoted on the OTCQB for the five days prior to the date on which KCC elects to exercise the Warrant. The Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis using the formula contained therein. |
Stock Options
Stock Options | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Notes to Financial Statements | ||
Note 6. Stock Options | On June 20, 2013, the Companys Board adopted the 2013 Long-Term Incentive Plan and on November 15, 2013, a stockholder owning a majority of the Companys issued and outstanding stock approved adoption to the 2013 Plan. Pursuant to the terms of the 2013 Plan, an aggregate of 20,000,000 shares of the Companys common stock are reserved for issuance to the Companys officers, directors, employees and consultants in order to attract and hire key technical personnel and management. Options granted to employees under the 2013 Plan, including directors and officers who are employees, may be incentive stock options or non-qualified stock options; options granted to others under the 2013 Plan are limited to non-qualified stock options. As of September 30, 2017, there were 19,338,572 shares available for grant. The 2013 Plan is administered by the Board or a committee designated by the Board. Subject to the provisions of the 2013 Plan, the Board has the authority to determine the officers, employees and consultants to whom options will be granted, the number of shares covered by each option, vesting rights and the terms and conditions of each option that is granted to them; however, no person may be granted in any of the Company's fiscal year, options to purchase more than 2,000,000 shares under the 2013 Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the 2013 Plan are exercisable no later than ten years after the date of grant. The exercise price per share of common stock for options granted under the 2013 Plan will be the fair market value of the Company's common stock on the date of grant, using the closing price of the Company's common stock on the last trading day prior to the date of grant, except for incentive stock options granted to a holder of ten percent or more of the Company's common stock, for whom the exercise price per share will not be less than 110% of the fair market value. No option can be granted under the 2013 Plan after June 20, 2023. Stock Option Activity The following table summarizes stock option activity for the nine months ended September 30, 2017: Number of Options Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at December 31, 2015 257,500 1.07 Grants 187,500 1.92 Forfeitures (40,000 ) 1.65 Exercises (20,000 ) 0.80 Outstanding at December 31, 2016 385,000 1.42 Grants 310,000 4.20 Exercises (150,000 ) 1.12 Outstanding at September 30, 2017 545,000 3.09 8.86 years 339,275 Exercisable at September 30, 2017 375,000 2.75 8.69 years 299,075 Available for grant at September 30, 2017 19,338,572 The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. There were 310,000 stock options granted during the nine months ended September 30, 2017 with a weighted-average grant date fair value of $3.38. There were 187,500 stock options granted during the nine months ended September 30, 2016 with a weighted-average grant date fair value of $1.41. During the nine months ended September 30, 2017, there were 150,000 options exercised on a cashless basis resulting in the issuance of 102,582 shares of common stock, with an aggregate intrinsic value of $397,100. There were no stock options exercised during the nine months ended September 30, 2016. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company's historical experience. The risk-free interest rate is based on a U.S. treasury note with maturity similar to the option award's expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The assumptions for volatility, expected life, dividend yield and risk-free interest rate for options granted are presented in the table below: 2017 2016 Risk-free interest rate 1.93% - 2.39% 1.23%-1.41% Expected life in years 5.5 10.0 5.5 Weighted Avg. Expected Volatility 98% - 106% 92% Expected dividend yield 0 0 The share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time is expensed ratably over the respective vesting periods. During the three months ended September 30, 2017 and 2016, the Company recognized $127,478 and $12,951, respectively, in share-based compensation. During the nine months ended September 30, 2017 and 2016, the Company recognized $748,350 and $287,238, respectively, in share-based compensation. Stock-based compensation has been included in the Consolidated Statement of Operations as follows: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Research and development $ 10,725 $ - $ 75,515 $ - General and administrative 116,753 12,951 672,835 287,238 Total $ 127,478 $ 12,951 $ 748,350 $ 287,238 The following table summarizes information about stock options outstanding and exercisable at September 30, 2017: Stock Options Outstanding Stock Options Exercisable Range of Exercise Prices Number of Shares Subject to Outstanding Options Weighted Average Contractual Life (years) Weighted Average Exercise Price Number of Shares Subject To Options Exercise Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price 0.80 10,000 6.87 0.80 10,000 6.87 0.80 1.05 55,000 6.50 1.05 35,000 6.50 1.05 1.25 7,500 7.71 1.25 7,500 7.71 1.25 1.34 7,500 7.75 1.34 7,500 7.75 1.34 1.65 10,000 8.09 1.65 10,000 8.09 1.65 1.70 7,500 8.04 1.70 7,500 8.04 1.70 1.91 130,000 8.46 1.91 130,000 8.46 1.91 2.28 7,500 8.81 2.28 7,500 8.81 2.28 4.20 310,000 9.62 4.20 160,000 9.62 4.20 Total 545,000 8.86 $ 3.09 375,000 8.69 $ 2.75 | On June 20, 2013, the Companys Board adopted the 2013 Long-Term Incentive Plan and on November 15, 2013, a stockholder owning a majority of the Companys issued and outstanding stock approved adoption to the 2013 Plan. Pursuant to the terms of the 2013 Plan, an aggregate of 20,000,000 shares of the Companys common stock are reserved for issuance to the Companys officers, directors, employees and consultants in order to attract and hire key technical personnel and management. Options granted to employees under the 2013 Plan, including directors and officers who are employees, may be incentive stock options or non-qualified stock options; options granted to others under the 2013 Plan are limited to non-qualified stock options. As of December 31, 2016, there were 19,595,000 shares available for grant. The 2013 Plan is administered by the Board or a committee designated by the Board. Subject to the provisions of the 2013 Plan, the Board has the authority to determine the officers, employees and consultants to whom options will be granted, the number of shares covered by each option, vesting rights and the terms and conditions of each option that is granted to them; however, no person may be granted in any of the Company's fiscal year, options to purchase more than 2,000,000 shares under the 2013 Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the 2013 Plan are exercisable no later than ten years after the date of grant. The exercise price per share of common stock for options granted under the 2013 Plan will be the fair market value of the Company's common stock on the date of grant, using the closing price of the Company's common stock on the last trading day prior to the date of grant, except for incentive stock options granted to a holder of ten percent or more of the Company's common stock, for whom the exercise price per share will not be less than 110% of the fair market value. No option can be granted under the 2013 Plan after June 20, 2023. Stock Option Activity The following table summarizes stock option activity for the period ended December 31, 2016: Number of Options Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at December 31, 2014 185,000 0.83 Grants 80,000 1.54 Forfeitures (7,500 ) 1.43 Outstanding at December 31, 2015 257,500 1.07 Grants 187,500 1.92 Forfeitures (40,000 ) 1.65 Exercises (20,000 ) 0.80 Outstanding at December 31, 2016 385,000 1.42 8.30 years 277,625 Exercisable at December 31, 2016 347,500 1.44 8.36 years 244,925 Available for grant at December 31, 2016 19,595,000 The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. There were 187,500 stock options granted during the year ended December 31, 2016 with a weighted-average grant date fair value of $1.41. There were 80,000 stock options granted during the year ended December 31, 2015 with a weighted-average grant date fair value of $1.18. There were 20,000 options exercised on a cashless basis during the year ended December 31, 2016, with an aggregate intrinsic value of $36,000. There were no stock options exercised during the year ended December 31, 2015. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company's historical experience. The risk-free interest rate is based on a U.S. treasury note with maturity similar to the option award's expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The assumptions for volatility, expected life, dividend yield and risk-free interest rate for options granted are presented in the table below: 2016 2015 Risk-free interest rate 1.23%-1.41% 1.49%-1.70% Expected life in years 5.5 5.0 Weighted Avg. Expected Volatility 92% 88.4105.3% Expected dividend yield 0 0 The fair value of the Companys stock options is expensed ratably over their respective vesting periods. During the years ended December 31, 2016 and 2015, the Company recognized $282,262 and $59,122, respectively, in share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time Stock-based compensation expense is recognized as general and administrative expenses. As of December 31, 2016, the Company had $8,404 of unrecognized compensation cost related to unvested stock options which is expected to be recognized over a period of 2.25 years. The following table summarizes information about stock options outstanding and exercisable at December 31, 2016: Stock Options Outstanding Stock Options Exercisable Range of Exercise Prices Number of Shares Subject to Outstanding Options Weighted Average Contractual Life (years) Weighted Average Exercise Price Number of Shares Subject To Options Exercise Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price $ 0.65 40,000 7.01 $ 0.65 40,000 7.01 $ 0.65 0.75 40,000 6.92 0.75 40,000 6.92 0.75 0.80 30,000 7.62 0.80 30,000 7.62 0.80 1.05 55,000 7.25 1.05 25,000 7.25 1.05 1.25 7,500 8.46 1.25 7,500 8.46 1.25 1.34 7,500 8.50 1.34 7,500 8.50 1.34 1.65 10,000 8.84 1.65 10,000 8.84 1.65 1.70 7,500 8.79 1.70 7,500 8.79 1.70 1.91 180,000 9.21 1.91 180,000 9.21 1.91 2.28 7,500 9.56 2.28 - 9.56 2.28 Total 385,000 8.30 $ 1.42 347,500 8.36 $ 1.44 |
Commitments
Commitments | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Notes to Financial Statements | ||
Note 7. Commitments | Effective March 1, 2015, the Company entered into a lease agreement (the Lease) in the Pittsburgh Life Sciences Greenhouse at a monthly rate of $750. The Company has the option to terminate the Lease on the twelve month anniversary of the commencement date, upon one hundred and twenty days prior written notice. The Lease was renewed effective March 1, 2017 at a monthly rate of $800. On August 1, 2013, the Company and Vector Asset Management, Inc. (Vector) entered into a Consulting Agreement whereby Vector will assist the Company with identifying subject matter experts in the medical device and biotechnology industries and to assist the Company with its ongoing research, development and eventual commercialization of its Regeneration Technology (collectively, the Services). On May 1, 2016, Vector and the Company entered into an amendment to the consulting agreement. Pursuant to the amendment, the term of the agreement terminates only upon written notice, and the monthly consulting fee, in consideration of the Services, was increased to $6,800 from $5,000. No other changes were made to the agreement. In connection with the Companys anticipated regulatory filings, the Company has engaged StemCell Systems GmbH (StemCell Systems) to provide it with prototypes and related documents under various agreements. Pursuant to these engagements the Company incurred expenses of $39,708 and $24,000 during the three months ended September 30, 2017 and 2016, respectively, and $146,538 and $134,567 during the nine months ended September 30, 2017 and 2016, respectively. Dr. Gerlach, from whom the Company purchased the CellMist TM See also Note 8. Related Party Transactions. | Effective March 1, 2015, the Company entered into a lease agreement (the Lease) in the Pittsburgh Life Sciences Greenhouse at a monthly rate of $750. The Company has the option to terminate the Lease on the twelve month anniversary of the commencement date, upon one hundred and twenty days prior written notice. The Lease was renewed effective March 1, 2016 at a monthly rate of $800. Rent expense for the years ended December 31, 2016 and 2015 was $9,500 and $9,000, respectively. On August 1, 2013, the Company and Vector Asset Management, Inc. (Vector) entered into a Consulting Agreement whereby Vector will assist the Company with identifying subject matter experts in the medical device and biotechnology industries and to assist the Company with its ongoing research, development and eventual commercialization of its Regeneration Technology (collectively, the Services). On May 1, 2016, Vector and the Company entered into an amendment to the consulting agreement. Pursuant to the amendment, the term of the agreement terminates only upon written notice, and the monthly consulting fee, in consideration of the Services, was increased to $6,800 from $5,000. No other changes were made to the agreement. In connection with the Companys anticipated regulatory filings, the Company has engaged StemCell Systems GmbH (StemCell Systems) to provide it with prototypes and related documents. Pursuant to this engagement the Company incurred expenses of $184,517 and $194,336 in during the years ended December 31, 2016 and 2015, respectively. Dr. Gerlach, from whom the Company purchased the CellMist TM See also Note 9. Related Party Transactions. |
Related Party Transactions
Related Party Transactions | 9 Months Ended | |
Sep. 30, 2017 | Sep. 30, 2016 | |
Notes to Financial Statements | ||
Note 8. Related Party Transactions | As compensation for their service on the Board, Dr. Kirkland and Mr. Sierchio will receive an annual retainer of $6,000, payable in equal yearly installments in arrears and prorated for any partial years of service. Additionally, on March 15, 2016, the Company granted to each of Dr. Kirkland and Mr. Sierchio an incentive stock option to purchase up to 50,000 shares of the Companys common stock at an exercise price of $1.91 per share. The options became fully vested upon grant. On May 11, 2017, the Company granted to each of Dr. Kirkland and Mr. Sierchio an incentive stock option to purchase up to 75,000 shares of the Companys common stock at an exercise price of $4.20 per share. 37,500 of the May 11 grant vested immediately with the remaining 37,500 vesting in one year on May 11, 2018. The option strike prices equal the closing price of the Companys common stock on the day of grant. The Options may be exercised on a cashless basis using the formula contained therein. The law firm of Sierchio & Partners, LLP, of which Joseph Sierchio, one of the Companys directors, was a principal, has provided counsel to the Company since August 26, 2010 and beginning in September 2016, Mr. Sierchio became a partner at Satterlee Stephens LLP (Satterlee). Concurrently with Mr. Sierchios move to Satterlee, the Company engaged wih Satterlee to provide legal counsel with Mr. Sierchio maintaining his role as the Companys primary attorney. During the three months ended September 30, 2017 and 2016, the Company recognized $15,115 and $30,080 of fees for legal services billed by firms associated with Mr. Sierchio. During the nine months ended September 30, 2017 and 2016, the Company recognized $195,783 and $121,595 of fees for legal services billed by firms associated with Mr. Sierchio. Included in accounts payable, at September 30, 2017 and December 31, 2016, is $10,000 and $11,750, respectively, owed to Satterlee. Mr. Sierchio continues his role with the Company as a director. In connection with the Companys anticipated regulatory filings, the Company has engaged StemCell Systems to provide it with prototypes and related documents under various agreements. Pursuant to these engagements the Company incurred expenses of $39,708 and $24,000 during the three months ended September 30, 2017 and 2016, respectively, and $146,538 and $134,567 during the nine months ended September 30, 2017 and 2016, respectively. Dr. Gerlach, from whom the Company purchased the CellMist TM On September 25, 2014, the Company entered into a Charitable Grant Agreement with the University of Pittsburgh, pursuant to which the Company committed to provide a charitable donation to the University of Pittsburgh in the aggregate amount of $75,000. The Company paid the Grant in eight quarterly installments of $9,375, with the final payment made on July 22, 2016. Dr. Gerlach, from whom the Company purchased the CellMist TM Dr. Gerlach is entitled to payments for consulting services. During the three months ended September 30, 2017 and 2016, the Company recognized expenses related to Dr. Gerlach services of $10,000 and $9,200, respectively. During the nine months ended September 30, 2017 and 2016, the Company recognized expenses related to Dr. Gerlach services of $28,540 and $33,210, respectively. Accounts payable to Dr. Gerlach amounted to $10,000 and $18,540 at September 30, 2017 and December 31, 2016, respectively. On May 1, 2015, the Company entered into the Option Agreement with Dr. Gerlach, pursuant to which the Company obtained a one-year exclusive option to evaluate the Technology, for the purpose of determining whether the Company would like to purchase or license the Technology. Pursuant to the terms of the Option Agreement, the Company paid Dr. Gerlach a non-refundable fee of $24,000, payable in four quarterly installments of $6,000, with the first installment due on May 1, 2015. The entire $24,000 option payment was recognized as research and development expense during the period ended December 31, 2015. The final $6,000 payment was made on February 1, 2016. On September 9, 2016, the Company entered into the Loan Agreement with KCC whereby KCC agreed to loan the Company up to $900,000 at an interest rate of 7%. KCC provided the Company with an initial loan of $700,000; the remaining $200,000 may be loaned prior to December 31, 2017. The Note matures on December 31, 2017, and, beginning on the first anniversary of the Note, can be converted into shares of the Companys common stock at conversion rate equal to the lesser of: (i) $1.54; or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which KCC elects to convert the Note, subject to a floor price of $1.23. Per the Loan Agreement, the Company issued KCC a Series E Warrant to purchase up to 584,416 shares of the Companys common stock at a purchase price of the lesser of: (i) $1.54; or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant. The Series E Warrant is exercisable for a period of five years and may be exercised on a cashless basis, See Note 4. Debt for additional disclosure. On February 23, 2017, the Company entered into two of the February 2017 Loan Agreements with Sierchio and KCC pursuant to which Sierchio loaned the Company $25,000 and KCC loaned $395,000 at an interest rate of 7%. The February 2017 Notes mature on February 23, 2018, and, beginning on the one month anniversary, can be converted into shares of the Companys common stock at conversion rate equal to the lesser of: (i) $3.45; or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76. Per the February 2017 Loan Agreement, the Company issued Sierchio, and KCC a Series F Warrant to purchase up to 7,246 shares and 114,493 shares, respectively, of the Companys common stock at an exercise per share equal to the lesser of: (i) $3.45; or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant. The Series F Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis. See Note 4. Debt for additional disclosure. On July 21, 2017, the Company entered into the July 2017 Private Placement with KCC for the sale of 410,000 units at a price of $2.44 per unit for $1,000,400 in aggregate proceeds. Each unit consisted of one share of common stock and one Series G Warrant to purchase one (1) share of common stock at an exercise price of $2.68 per share through July 21, 2022. The warrants may be exercised on a cashless basis. On June 28, 2017, KCC exercised 114,493 Series F Warrants for $3.01 per share resulting in the issuance of 114,493 shares of common stock and proceeds of $344,624. March 1, 2017, KCC exercised 1,326,087 Series B Warrants and 3,092,637 Series C Warrants, on a cashless basis, resulting in the issuance of 4,273,831 shares of common stock. On February 17, 2017, Thomas Bold, the Companys President, CEO and Interim Chief Financial Officer exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 34,296 shares of common stock. On February 10, 2017, Joseph Sierchio, a member of the Companys board of directors, exercised options to purchase up to 70,000 shares, on a cashless basis, resulting in the issuance of 38,642 shares of common stock. On February 2, 2016, KCC exercised a portion of its Series B Warrant for 2,173,913 shares of the Companys common stock at an exercise price of $0.46 per share resulting in proceeds of $1,000,000. On February 2, 2017, Kenneth Kirkland, a member of the Companys board of directors, exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 29,642 shares of common stock. On January 10, 2017, Dr. Gerlach exercised a Series A Warrant to purchase up to 240,000 shares, on a cashless basis, resulting in the issuance of 204,571 shares of common stock. | As compensation for their service on the Board, Dr. Kirkland and Mr. Sierchio will receive an annual retainer of $6,000, payable in equal yearly installments in arrears and prorated for any partial years of service. Additionally, on March 15, 2016, the Company granted to each of Dr. Kirkland and Mr. Sierchio an incentive stock option to purchase up to 50,000 shares of the Companys common stock at an exercise price of $1.91 per share, the closing price of the Companys common stock on the day prior to the grant. The options became fully vested upon grant and may be exercised on a cashless basis using the formula contained therein. The law firm of Sierchio & Partners, LLP, of which Joseph Sierchio, one of the Companys directors, was a principal, has provided counsel to the Company since August 26, 2010. Beginning in September 2016, Mr. Sierchio became a partner at Satterlee Stephens LLP (Satterlee). Concurrently with Mr. Sierchios move to Satterlee, the Company engaged wih Satterlee to provide legal counsel with Mr. Sierchio maintaining his role as the Companys primary attorney. During the years ended December 31, 2016 and 2015, the Company recognized $168,775 and $101,700 of fees for legal services billed by firms associated with Mr. Sierchio. Included in accounts payable, at December 31, 2016, is $11,750 owed to Satterlee and at December 31, 2015, is $8,322 owed Sierchio & Partners, LLP. Mr. Sierchio continues his role with the Company as a director. In connection with the Companys anticipated FDA and other regulatory filings, the Company engaged StemCell Systems to provide it with prototypes and related documents. Pursuant to this engagement the Company incurred expenses of $184,517 and $194,336 during the years ended December 31, 2016 and 2015, respectively. Dr. Gerlach, from whom the Company purchased the CellMist TM On September 25, 2014, the Company entered into a Charitable Grant Agreement with the University, pursuant to which the Company committed to provide a charitable donation to the University in the aggregate amount of $75,000. The Company paid the Grant in eight quarterly installments of $9,375, with the final payment made on July 22, 2016. Dr. Gerlach, from whom the Company purchased the CellMist TM Dr. Gerlach is entitled to payments for consulting services. During the years ended December 31, 2016 and 2015, the Company recognized expenses related to Dr. Gerlach services of $42,480 and $36,720, respectively. On May 1, 2015, the Company entered into the Option Agreement with Dr. Gerlach, pursuant to which the Company obtained a one-year exclusive option to evaluate the Technology, for the purpose of determining whether the Company would like to purchase or license the Technology. Pursuant to the terms of the Option Agreement, the Company paid Dr. Gerlach a non-refundable fee of $24,000, payable in four quarterly installments of $6,000, with the first installment due on May 1, 2015. The entire $24,000 option payment was recognized as research and development expense during the period ended December 31, 2015. The final $6,000 payment was made on February 1, 2016. On September 9, 2016, the Company entered into a loan agreement with KCC. Pursuant to the terms of the Loan Agreement, KCC agreed to loan the Company up to $900,000 at an annual interest rate of 7% per year, compounded quarterly. KCC provided the Company with an initial loan in the amount of $700,000, which was evidenced by the Note; the remaining $200,000 may be loaned prior to December 31, 2017, upon the mutual agreement of the Company and KCC. The Note, including any interest due thereon, may be prepaid at any time without penalty. The Note matures on December 31, 2017, and, beginning on the first anniversary of the Note, can be converted, at KCCs sole discretion, into shares of the Companys common stock at conversion rate equal to the lesser of: (i) $1.54, or the closing price of the Companys common stock on the day prior to the issuance of the Note or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which KCC elects to convert the Note, subject to a floor price of $1.23. Per the Loan Agreement, the Company issued KCC a Series E Warrant to purchase up to 584,416 shares of the Companys common stock at a purchase price of the lesser of: (i) $1.54, the closing price of the Companys common stock on the day prior to issuance of the Series E Warrant; or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant. The Series E Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis. On February 2, 2016, KCC exercised a portion of its Series B Warrant for 2,173,913 shares of the Companys common stock at an exercise price of $0.46 per share resulting in proceeds of $1,000,000. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Note 10. Income Taxes | Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. There is no current or deferred tax expense for 2016 and 2015, due to the Companys loss position. Realization of the future tax benefits related to the deferred tax assets is dependent on many factors, including the Companys ability to generate taxable income within the net operating loss carryforward period. Management has considered these factors in reaching its conclusion as to the valuation allowance for financial reporting purposes and has recorded a full valuation allowance against the deferred tax asset. The income tax effect, utilizing a 34% income tax rate, of temporary differences comprising the deferred tax assets and deferred tax liabilities is a result of the following at December 31: 2016 2015 Deferred tax assets: Net operating loss and contribution carryforwards $ 3,217,000 $ 2,646,000 Intangible asset 158,000 84,000 Capital loss carryforward 236,000 - Stock-based compensation 139,000 46,000 3,750,000 2,776,000 Valuation allowance (3,750,000 ) (2,776,000 ) Net deferred tax assets $ - $ - The 2016 increase in the valuation allowance was $974,000 (2015: $154,000). The Company has available net operating loss and contribution carryforwards of approximately $9,302,000 for tax purposes to offset future taxable income which expire commencing 2018 through to the year 2036. The capital loss carryforward expires during 2018. Pursuant to the Tax Reform Act of 1986, annual utilization of the Companys net operating loss and contribution carryforwards may be limited if a cumulative change in ownership of more than 50% is deemed to occur within any three-year period. The tax years 2014 through 2016 remain open to examination by federal agencies and other jurisdictions in which it operates. A reconciliation between the statutory federal income tax rate (34%) and the effective rate of income tax expense for the years ended December 31 follows: 2016 2015 Statutory federal income tax rate 34 % 34 % Permanent differences and other 13 % (22 )% Valuation allowance (47 )% (12 )% 0 % 0 % |
Subsequent Events
Subsequent Events | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Notes to Financial Statements | ||
Note 9. Subsequent Events | Management has reviewed material events subsequent of the period ended September 30, 2017 and prior to the filing of financial statements in accordance with FASB ASC 855 Subsequent Events. On October 16, 2017, the Company completed a self-directed offering of 920,000 shares of the Company common stock at a price of $2.50 per share for $2,300,000 in aggregate proceeds. Additionally, each purchaser received one stock purchase warrant for each share of stock purchased for no additional consideration. Each warrant is exercisable at a price of $2.75 per share for a period of five years. The warrants may be exercised on a cashless basis. | On January 10, 2017, Dr. Gerlach exercised a Series A Warrant to purchase up to 240,000 shares, on a cashless basis, resulting in the issuance of 204,571 shares of common stock. On February 2, 2017, Kenneth Kirkland, a member of the Companys board of directors, exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 29,642 shares of common stock. On February 10, 2017, Joseph Sierchio, a member of the Companys board of directors, exercised options to purchase up to 70,000 shares, on a cashless basis, resulting in the issuance of 38,642 shares of common stock. On February 17, 2017, Thomas Bold, the Companys President, CEO and Interim Chief Financial Officer exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 34,296 shares of common stock. On February 23, 2017, the Company entered into two separate loan agreements containing identical terms (the February 2017 Loan Agreements) with Joseph Sierchio (Sierchio) and KCC (collectively, the Holders). Pursuant to the terms of the February 2017 Loan Agreements, Sierchio agreed to loan the Company $25,000 and KCC agreed to loan the Company $395,000 at an annual interest rate of 7% per year, compounded quarterly. Each loan was evidenced by a convertible promissory note (the February 2017 Notes). The February 2017 Notes, including any interest due thereon, may not be prepaid without the consent of the Holders. The February 2017 Notes mature on February 23, 2018, and, beginning on the one month anniversary, can be converted, at the Holders sole discretion, into shares of the Companys common stock at conversion rate equal to the lesser of: (i) $3.45, the closing price of the Companys common stock on the day prior to the issuance of the February 2017 Notes or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76. Per the February 2017 Loan Agreement, the Company issued Sierchio and KCC a Series F Stock Purchase Warrant (the Series F Warrant) to purchase up to 7,246 shares and 114,193 shares, respectively, of the Companys common stock at an exercise per share equal to the lesser of: (i) $3.45, the closing price of the Companys common stock on the day prior to issuance of the Series F Warrant; or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant. The Series F Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis. The February 2017 Loan Agreements provide the Holders with registration rights for all of the shares issuable upon conversion of the February 2017 Notes, including exercise of the Series F Warrants, beginning on the first anniversary of the February 2017 Loan Agreements. On March 1, 2017, KCC exercised a Series B Warrant to purchase up to 1,326,087 shares, on a cashless basis, resulting in the issuance of 1,181,194 shares of common stock. On March 1, 2017, KCC exercised a Series C Warrant to purchase up to 3,500,000 shares, on a cashless basis, resulting in the issuance of 3,092,637 shares of common stock. On March 9, 2017, the Company entered into a loan agreement with an investor (the Investor) on the same terms as the February 2017 Loan Agreements (the March 2017 Loan Agreement). Pursuant to the terms of the March 2017 Loan Agreement, the Investor agreed to loan the Company $25,000 at an annual interest rate of 7% per year, compounded quarterly. The loan was evidenced by a convertible promissory note (the March 2017 Note). The March 2017 Note, including any interest due thereon, may not be prepaid without the consent of the Investor. The March 2017 Note mature on February 23, 2018, and, beginning on the one month anniversary, can be converted, at the Investors sole discretion, into shares of the Companys common stock at conversion rate equal to the lesser of: (i) $3.45, or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which the Investor elects to convert the March 2017 Note, subject to a floor price of $2.76. Per the March 2017 Loan Agreement, the Company issued the Investor a Series F Warrant to purchase up to 7,246 shares of the Companys common stock at an exercise per share equal to the lesser of: (i) $3.45, or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which the Investor elects to exercise their Series F Warrant. The Series F Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis. |
Basis of Presentation, Organiza
Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share (Policies) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Basis Of Presentation Organization Going Concern Recent Accounting Pronouncements And Earnings Loss Per Share Policies | ||
Principles of Consolidation | These consolidated financial statements have been prepared in accordance with US GAAP and include the accounts of the Company and its wholly owned subsidiary, RenovaCare Sciences. All significant intercompany transactions and balances have been eliminated. RenovaCare Sciences was incorporated under the laws of the State of Nevada on June 12, 2013. | |
Applicable Accounting Guidance | Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification. In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09, Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting (Topic 718), which is intended to simplify several aspects of the accounting for share-based payment award transactions. The guidance will be effective for the fiscal year beginning after December 15, 2016, including interim periods within that year. The Company does not expect adoption of ASU 2016-09 to have a material impact on its financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes ASC Topic 840, Leases, and creates a new topic, ASC Topic 842, Leases. ASU 2016-02 requires lessees to recognize a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months on its balance sheet. ASU 2016-02 also expands the required quantitative and qualitative disclosures surrounding leases. ASU 2016-02 is effective for the Company beginning January 1, 2019. Early adoption is permitted. The Company has determined that the adoption of ASU 2016-02 will currently have no impact on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes (ASU 2015-17). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. ASU 2015-17 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Early adoption is permitted and the standard may be applied either retrospectively or on a prospective basis to all deferred tax assets and liabilities. The Company has determined that the adoption of ASU 2015-17 will currently have no impact on its consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017, and early adoption is permitted. The Company has determined that the adoption of ASU 2014-09 will currently have no impact on its consolidated financial statements. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Companys previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion other than as discussed above. The Company believes that none of the new standards will have a significant impact on the financial statements. | |
Accounting Estimates | The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results, as determined by future events, may differ from these estimates. | |
Cash and Cash Equivalents | The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents may at times exceed federally insured limits. | |
Fair Value Measurement | The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1. Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. The Company has no assets or liabilities valued with Level 1 inputs. Level 2. Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. The Company has no assets or liabilities valued with Level 2 inputs. Level 3. Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company has no assets or liabilities valued with Level 3 inputs. | |
Fair Value of Financial Instruments | The carrying value of cash and cash equivalents, accounts payable, and contract and contribution payable, approximate their fair value because of the short-term nature of these instruments and their liquidity. It is not practical to determine the fair value of the Companys note payable and accrued interest due to the complex terms. Management is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments. | |
Research and Development Costs | The Company intends to outsource its research and development efforts and expense related costs as incurred, including the cost of manufacturing product for testing, licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and other intellectual property acquired will be capitalized as it relates to particular research and development projects that may have alternative future uses. | |
Equipment | Equipment is carried at cost, less accumulated depreciation and amortization. Major improvements are capitalized, while repair and maintenance are expensed when incurred. Renewals and betterments that materially extend the life of the assets are capitalized. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in income for the period. Depreciation is computed on a straight-line basis over estimated useful lives of the related assets. The estimated useful lives of depreciable assets are: Estimated Useful Lives Office equipment 3-5 years Furniture & equipment 5-7 years | |
Intangible Assets | The Companys intangible asset consists primarily of the CellMist TM The Company assessed the following qualitative factors that could affect any change in the fair value of the intangible asset: analysis of the technology's current phase, additional testing necessary to bring the technology to market, development of competing products, changes in projections caused by delays, changes in regulations, changes in the market for the technology and changes in cost projections to bring the technology to market. Based on a qualitative assessment, management concluded that a positive assertion can be made from the qualitative assessment that it is more likely than not that the intangible asset related to the CellMist TM | |
Stock Options | The Company measures all stock-based compensation awards using a fair value method on the date of grant and recognizes such expense in its consolidated financial statements over the requisite service period. The Company uses the Black-Scholes pricing model to determine the fair value of stock-based compensation awards on the date of grant. The Black-Scholes pricing model requires management to make assumptions regarding option lives, expected volatility, and risk free interest rates. The Companys policy is to issue new shares upon exercise of options. | |
Income Taxes | The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively. | |
Related Party Transactions | A related party is generally defined as (i) any person who holds 10% or more of the Company's securities and their immediate families; (ii) the Company's management; (iii) someone who directly or indirectly controls, is controlled by or is under common control with the Company; or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. See Note 9. Related Party Transactions, for further discussion. | |
Basis of Presentation | The unaudited financial statements of RenovaCare, Inc. (the Company) as of September 30, 2017, and for the three and nine months ended September 30, 2017 and 2016, have been prepared in accordance with generally accepted accounting principles (GAAP) in the United States for interim financial reporting and include the Companys wholly-owned subsidiary, RenovaCare Sciences. Accordingly, they do not include all of the disclosures required by accounting principles generally accepted in the United States for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016, as filed with the Securities and Exchange Commission as part of the Companys Form 10-K. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the interim financial information have been included. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year. | |
Organization | RenovaCare, Inc., together with its wholly owned subsidiary, focuses on the acquisition, research, development and, if warranted, commercialization of autologous (using a patient's own cells) cellular therapies that can be used for medical and aesthetic applications. On July 12, 2013, the Company, through its wholly owned subsidiary, RenovaCare Sciences Corp., completed the acquisition of its flagship technologies (collectively, the CellMist TM The CellMist TM CellMist TM SkinGun TM TM TM | |
Going Concern | The Company's activities have consisted principally of performing research and development activities and raising capital. These activities are subject to significant risks and uncertainties, including possible failure of preclinical testing and failing to secure additional funding before achieving sustainable revenue and profit from operations. The Company's ability to fund the development of its cellular therapies will depend on the amount and timing of cash receipts from future financing activities. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Companys ability to establish itself as a profitable business. The Company does not have any commercialized products, has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies. Over the past year, the Company has been funded through the sale of equity securities and proceeds from convertible promissory notes. As of September 30, 2017, the Company had approximately $1,149,604 of cash. On October 16, 2017, the Company completed a private placement with a group of private investors, whereby the Company received $2,300,000 from the sale of common stock and warrants. The Company believes that, as a result, it currently has sufficient cash to meet its funding requirements over the next year. However, the Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it will need to raise additional capital to accomplish its business plan. The Company expects to seek to obtain additional funding through the sale of its securities. There can be no assurance as to the availability or terms upon which such financing and capital might be available. | |
Recent Accounting Pronouncements | Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification. In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09, Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting (Topic 718), which is intended to simplify several aspects of the accounting for share-based payment award transactions. The guidance was effective for annual periods beginning after December 31, 2016, with early adoption permitted. The Company adopted the guidance with no material impact on its financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes ASC Topic 840, Leases, and creates a new topic, ASC Topic 842, Leases. ASU 2016-02 requires lessees to recognize a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months on its balance sheet. ASU 2016-02 also expands the required quantitative and qualitative disclosures surrounding leases. ASU 2016-02 is effective for the Company beginning January 1, 2019. Early adoption is permitted. The Company has determined that the adoption of ASU 2016-02 will currently have no impact on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes (ASU 2015-17). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. The guidance was effective for annual periods beginning after December 31, 2016, with early adoption permitted. The Company adopted the guidance with no material impact on its consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017, and early adoption is permitted. The Company has determined that the adoption of ASU 2014-09 will currently have no impact on its consolidated financial statements. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Companys previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion other than as discussed above. The Company believes that none of the new standards will have a significant impact on the financial statements. | |
Earnings (Loss) Per Share | The Company presents both basic and diluted earnings per share (EPS) amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive. Following is the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2017 and 2016: Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (851,446 ) $ (302,636 ) $ (2,693,646 ) $ (1,610,880 ) Denominator: Weighted average number of common shares outstanding 75,123,280 69,955,847 73,837,107 69,695,772 Basic and diluted EPS $ (0.01 ) $ (0.00 ) $ (0.04 ) $ (0.02 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 545,000 445,000 545,000 445,000 Warrants 2,689,158 7,380,503 2,689,158 7,380,503 Convertible debt 647,813 623,067 647,813 623,067 Total shares not included in the computation of diluted losses per share 3,881,971 8,448,570 3,881,971 8,448,570 | The Company presents both basic and diluted earnings per share ("EPS") amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive. Following is the computation of basic and diluted net loss per share for the years ended December 31, 2016 and 2015: Years Ended December 31, 2016 2015 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (2,077,889 ) $ (1,318,507 ) Denominator: Weighted average number of common shares outstanding 69,772,485 67,233,254 Basic and diluted EPS $ (0.03 ) $ (0.02 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 385,000 257,500 Warrants 7,280,503 8,970,000 Convertible debt 464,428 - Total shares not included in the computation of diluted losses per share 8,129,931 9,227,500 |
Basis of Presentation, Organi19
Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share (Tables) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Basis Of Presentation Organization Going Concern Recent Accounting Pronouncements And Earnings Loss Per Share Tables | ||
Summary of computation of basic and diluted net loss per share | Following is the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2017 and 2016: Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (851,446 ) $ (302,636 ) $ (2,693,646 ) $ (1,610,880 ) Denominator: Weighted average number of common shares outstanding 75,123,280 69,955,847 73,837,107 69,695,772 Basic and diluted EPS $ (0.01 ) $ (0.00 ) $ (0.04 ) $ (0.02 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 545,000 445,000 545,000 445,000 Warrants 2,689,158 7,380,503 2,689,158 7,380,503 Convertible debt 647,813 623,067 647,813 623,067 Total shares not included in the computation of diluted losses per share 3,881,971 8,448,570 3,881,971 8,448,570 | Years Ended December 31, 2016 2015 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (2,077,889 ) $ (1,318,507 ) Denominator: Weighted average number of common shares outstanding 69,772,485 67,233,254 Basic and diluted EPS $ (0.03 ) $ (0.02 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 385,000 257,500 Warrants 7,280,503 8,970,000 Convertible debt 464,428 - Total shares not included in the computation of diluted losses per share 8,129,931 9,227,500 |
Summary of computation of depreciation | Estimated Useful Lives Office equipment 3-5 years Furniture & equipment 5-7 years |
Contract and Contribution Payab
Contract and Contribution Payable (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Contract And Contribution Payable Tables | |
Summary of contract and contribution payable | 2016 2015 Contribution payable to the University of Pittsburgh, in quarterly installments of $9,375, through July 2016 $ - $ 28,125 Contract payable to Dr. Jorg Gerlach in connection with the APA. $50,000 was due on December 31, 2016 and $100,000 is due on December 31, 2017 150,000 200,000 Contract for option agreement purchase - 6,000 Total 150,000 234,125 Less: current portion (150,000 ) (134,125 ) Long-term portion $ - $ 100,000 |
Common Stock and Warrants (Tabl
Common Stock and Warrants (Tables) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Common Stock And Warrants Tables | ||
Summary of warrants outstanding | The following table summarizes information about warrants outstanding at September 30, 2017 and December 31, 2016: Shares of Common Stock Issuable from Warrants Outstanding as of Weighted Average September 30, December 31, Exercise Description 2017 2016 Price Expiration Series A 720,000 960,000 $ 0.35 July 12, 2019 Series B - 1,326,087 $ 0.46 November 29, 2018 Series C - 3,500,000 $ 0.49 November 29, 2018 Series D 910,000 910,000 $ 1.10 June 5, 2020 Series E 584,416 584,416 $ 1.54 September 8, 2021 Series F 14,492 - $ 3.45 February 23, 2022 & March 9, 2022 Series G 460,250 - $ 2.68 July 21, 2022 Total 2,689,158 7,280,503 | Shares of Common Stock Issuable from Warrants Outstanding as of Weighted December 31, Average Description 2016 2015 Exercise Price Expiration Series A 960,000 960,000 $ 0.35 July 12, 2019 Series B 1,326,087 3,500,000 $ 0.46 November 29, 2018 Series C 3,500,000 3,500,000 $ 0.49 November 29, 2018 Series D 910,000 1,010,000 $ 1.10 June 5, 2020 Series E 584,416 - $ 1.13 September 8, 2021 Total 7,280,503 8,970,000 |
Stock Options (Tables)
Stock Options (Tables) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Stock Options Tables | ||
Summary of stock option activity | The following table summarizes stock option activity for the nine months ended September 30, 2017: Number of Options Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at December 31, 2015 257,500 1.07 Grants 187,500 1.92 Forfeitures (40,000 ) 1.65 Exercises (20,000 ) 0.80 Outstanding at December 31, 2016 385,000 1.42 Grants 310,000 4.20 Exercises (150,000 ) 1.12 Outstanding at September 30, 2017 545,000 3.09 8.86 years 339,275 Exercisable at September 30, 2017 375,000 2.75 8.69 years 299,075 Available for grant at September 30, 2017 19,338,572 | Number of Options Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at December 31, 2014 185,000 0.83 Grants 80,000 1.54 Forfeitures (7,500 ) 1.43 Outstanding at December 31, 2015 257,500 1.07 Grants 187,500 1.92 Forfeitures (40,000 ) 1.65 Exercises (20,000 ) 0.80 Outstanding at December 31, 2016 385,000 1.42 8.30 years 277,625 Exercisable at December 31, 2016 347,500 1.44 8.36 years 244,925 Available for grant at December 31, 2016 19,595,000 |
Summary of assumption of stock option activity | The assumptions for volatility, expected life, dividend yield and risk-free interest rate for options granted are presented in the table below: 2017 2016 Risk-free interest rate 1.93% - 2.39% 1.23%-1.41% Expected life in years 5.5 10.0 5.5 Weighted Avg. Expected Volatility 98% - 106% 92% Expected dividend yield 0 0 | 2016 2015 Risk-free interest rate 1.23%-1.41% 1.49%-1.70% Expected life in years 5.5 5.0 Weighted Avg. Expected Volatility 92% 88.4105.3% Expected dividend yield 0 0 |
Stock-based compensation included in consolidated statement of operations | Stock-based compensation has been included in the Consolidated Statement of Operations as follows: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Research and development $ 10,725 $ - $ 75,515 $ - General and administrative 116,753 12,951 672,835 287,238 Total $ 127,478 $ 12,951 $ 748,350 $ 287,238 | |
Summary of stock options outstanding and exercisable | The following table summarizes information about stock options outstanding and exercisable at September 30, 2017: Stock Options Outstanding Stock Options Exercisable Range of Exercise Prices Number of Shares Subject to Outstanding Options Weighted Average Contractual Life (years) Weighted Average Exercise Price Number of Shares Subject To Options Exercise Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price 0.80 10,000 6.87 0.80 10,000 6.87 0.80 1.05 55,000 6.50 1.05 35,000 6.50 1.05 1.25 7,500 7.71 1.25 7,500 7.71 1.25 1.34 7,500 7.75 1.34 7,500 7.75 1.34 1.65 10,000 8.09 1.65 10,000 8.09 1.65 1.70 7,500 8.04 1.70 7,500 8.04 1.70 1.91 130,000 8.46 1.91 130,000 8.46 1.91 2.28 7,500 8.81 2.28 7,500 8.81 2.28 4.20 310,000 9.62 4.20 160,000 9.62 4.20 Total 545,000 8.86 $ 3.09 375,000 8.69 $ 2.75 | Stock Options Outstanding Stock Options Exercisable Range of Exercise Prices Number of Shares Subject to Outstanding Options Weighted Average Contractual Life (years) Weighted Average Exercise Price Number of Shares Subject To Options Exercise Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price $ 0.65 40,000 7.01 $ 0.65 40,000 7.01 $ 0.65 0.75 40,000 6.92 0.75 40,000 6.92 0.75 0.80 30,000 7.62 0.80 30,000 7.62 0.80 1.05 55,000 7.25 1.05 25,000 7.25 1.05 1.25 7,500 8.46 1.25 7,500 8.46 1.25 1.34 7,500 8.50 1.34 7,500 8.50 1.34 1.65 10,000 8.84 1.65 10,000 8.84 1.65 1.70 7,500 8.79 1.70 7,500 8.79 1.70 1.91 180,000 9.21 1.91 180,000 9.21 1.91 2.28 7,500 9.56 2.28 - 9.56 2.28 Total 385,000 8.30 $ 1.42 347,500 8.36 $ 1.44 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Income Taxes Tables | |
Schedule of deferred tax assets and liabilities | 2016 2015 Deferred tax assets: Net operating loss and contribution carryforwards $ 3,217,000 $ 2,646,000 Intangible asset 158,000 84,000 Capital loss carryforward 236,000 - Stock-based compensation 139,000 46,000 3,750,000 2,776,000 Valuation allowance (3,750,000 ) (2,776,000 ) Net deferred tax assets $ - $ - |
Reconciliation of the statutory federal income tax expense (benefit) | 2016 2015 Statutory federal income tax rate 34 % 34 % Permanent differences and other 13 % (22 )% Valuation allowance (47 )% (12 )% 0 % 0 % |
Basis of Presentation, Organi24
Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share (Details ) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2015 | |
Basic and Diluted EPS Computation | |||||||
Loss available to common stockholders' | $ (851,446) | $ (302,636) | $ (2,693,646) | $ (1,610,880) | $ (2,077,889) | $ (1,318,507) | $ (1,318,507) |
Denominator: | |||||||
Weighted average number of common shares outstanding | 75,123,280 | 69,955,847 | 73,837,107 | 69,695,772 | 69,772,485 | 67,233,254 | |
Basic and diluted EPS | $ (0.01) | $ 0 | $ (0.04) | $ (0.02) | $ (0.03) | $ (0.02) | |
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: | |||||||
Total shares not included in the computation of diluted losses per share | 3,881,971 | 8,448,570 | 3,881,971 | 8,448,570 | 8,129,931 | 9,227,500 | |
Stock options [Member] | |||||||
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: | |||||||
Total shares not included in the computation of diluted losses per share | 545,000 | 445,000 | 545,000 | 445,000 | 385,000 | 257,500 | |
Warrant [Member] | |||||||
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: | |||||||
Total shares not included in the computation of diluted losses per share | 2,689,158 | 7,380,503 | 2,689,158 | 7,380,503 | 7,280,503 | 8,970,000 | |
Convertible debt [Member] | |||||||
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: | |||||||
Total shares not included in the computation of diluted losses per share | 647,813 | 623,067 | 647,813 | 623,067 | 464,428 |
Basis of Presentation, Organi25
Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share (Narrative) - USD ($) | 1 Months Ended | |||||
Oct. 16, 2017 | Sep. 30, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Cash and cash equivalents | $ 1,149,604 | $ 418,031 | $ 687,747 | $ 397,589 | $ 683,098 | |
Private Placement Member | ||||||
Proceeds from sale of common stock and warrants | 2,300,000 |
Organization, Nature and Cont26
Organization, Nature and Continuance of Operations (Details Narrative) - USD ($) | 12 Months Ended | ||
Dec. 31, 2016 | Sep. 30, 2017 | Dec. 31, 2015 | |
Organization Nature And Continuance Of Operations Details Narrative | |||
Accumulated deficit | $ (11,051,584) | $ (13,745,230) | $ (8,973,695) |
Convertible promissory notes | $ 445,000 | ||
Expire | March 3, 2035 |
Significant Accounting Polici27
Significant Accounting Policies (Details) | 12 Months Ended |
Dec. 31, 2016 | |
Office equipment [Member] | Minimum [Member] | |
Estimated Useful Lives | 3 years |
Office equipment [Member] | Maximum [Member] | |
Estimated Useful Lives | 5 years |
Furniture & equipment [Member] | Minimum [Member] | |
Estimated Useful Lives | 5 years |
Furniture & equipment [Member] | Maximum [Member] | |
Estimated Useful Lives | 7 years |
Significant Accounting Polici28
Significant Accounting Policies (Details 1) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2015 | |
Basic and Diluted EPS Computation | |||||||
Loss available to common stockholders' | $ (851,446) | $ (302,636) | $ (2,693,646) | $ (1,610,880) | $ (2,077,889) | $ (1,318,507) | $ (1,318,507) |
Denominator: | |||||||
Weighted average number of common shares outstanding | 75,123,280 | 69,955,847 | 73,837,107 | 69,695,772 | 69,772,485 | 67,233,254 | |
Basic and diluted EPS | $ (0.01) | $ 0 | $ (0.04) | $ (0.02) | $ (0.03) | $ (0.02) | |
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: | |||||||
Total shares not included in the computation of diluted losses per share | 3,881,971 | 8,448,570 | 3,881,971 | 8,448,570 | 8,129,931 | 9,227,500 | |
Stock options [Member] | |||||||
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: | |||||||
Total shares not included in the computation of diluted losses per share | 545,000 | 445,000 | 545,000 | 445,000 | 385,000 | 257,500 | |
Warrant [Member] | |||||||
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: | |||||||
Total shares not included in the computation of diluted losses per share | 2,689,158 | 7,380,503 | 2,689,158 | 7,380,503 | 7,280,503 | 8,970,000 | |
Convertible debt [Member] | |||||||
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: | |||||||
Total shares not included in the computation of diluted losses per share | 647,813 | 623,067 | 647,813 | 623,067 | 464,428 |
Significant Accounting Polici29
Significant Accounting Policies (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Significant Accounting Policies Details Narrative | ||
Impairment loss | $ 10,000 |
Assets _ Intellectual Property
Assets – Intellectual Property (Details Narrative) - USD ($) | 1 Months Ended | 12 Months Ended | ||
Jul. 31, 2013 | Dec. 31, 2016 | Sep. 30, 2017 | Dec. 31, 2015 | |
Acquisition related costs | $ 52,852 | |||
Closing cash payment | 100,002 | |||
Intangible Assets | $ 152,854 | $ 152,854 | $ 152,854 | |
Asset purchase agreement [Member] | Dr. Gerlach [Member] | ||||
Acquisition related costs | $ 52,852 | |||
Closing cash payment | $ 100,002 |
Contract Payable (Details Narra
Contract Payable (Details Narrative) - USD ($) | Jun. 09, 2014 | Dec. 31, 2017 | Sep. 30, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 |
Amended APA provided for cash payments | $ 300,000 | |||||
Purchase payable amount | $ 100,000 | $ 50,000 | $ 50,000 | $ 100,000 | ||
Contract and contribution payable | $ 100,000 | $ 150,000 | $ 134,125 | |||
Subsequent Event [Member] | ||||||
Purchase payable amount | $ 100,000 | |||||
Dr. Gerlach [Member] | ||||||
Contract and contribution payable | $ 100,000 |
Contract and Contribution Pay32
Contract and Contribution Payable (Details) - USD ($) | Sep. 30, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Total | $ 150,000 | $ 234,125 | |
Less: current portion | $ (100,000) | (150,000) | (134,125) |
Long-term portion | 100,000 | ||
Contribution payable [Member] | |||
Total | 28,125 | ||
Contract payable [Member] | |||
Total | 150,000 | 200,000 | |
Contract for option agreement [Member] | |||
Total | $ 6,000 |
Contract and Contribution Pay33
Contract and Contribution Payable (Details Narrative) - USD ($) | May 01, 2015 | Jun. 09, 2014 | Sep. 25, 2014 | Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2017 | Dec. 31, 2014 |
Accounts payable | $ 101,911 | $ 101,911 | $ 71,563 | ||||||||
Contract and contribution payable, less current portion | 100,000 | ||||||||||
Amended APA provided for cash payments | $ 300,000 | ||||||||||
Purchase payable amount | 50,000 | 50,000 | $ 100,000 | $ 100,000 | |||||||
Research and development expense | $ 139,819 | $ 45,381 | $ 363,785 | $ 231,013 | 309,503 | $ 281,218 | |||||
Charitable Grant Agreement [Member] | |||||||||||
Donation to the University | $ 75,000 | ||||||||||
Donation periodic payment | $ 9,375 | ||||||||||
Dr. Gerlach [Member] | |||||||||||
Accounts payable | $ 150,000 | ||||||||||
Dr. Gerlach [Member] | Option agreement [Member] | |||||||||||
Due to related party periodic payment | $ 6,000 | ||||||||||
Research and development expense | $ 24,000 |
Debt (Details Narrative)
Debt (Details Narrative) - USD ($) | Sep. 09, 2016 | Jul. 27, 2017 | Feb. 28, 2017 | Feb. 28, 2017 | Feb. 23, 2017 | Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016 | Dec. 31, 2015 | Feb. 27, 2017 |
Interest expense | $ 20,775 | $ 2,819 | $ 56,641 | $ 2,819 | $ (15,220) | |||||||
Accretion of debt discount | $ (256,667) | $ (30,753) | $ (675,077) | $ (30,753) | $ (165,481) | |||||||
Common stock shares reserved under stock option plan | 102,582 | 102,582 | 19,595,000 | |||||||||
Exercise Price | $ 1.25 | |||||||||||
Market price of common stock | $ 1.54 | |||||||||||
Estimated volatility | 92.30% | |||||||||||
Risk free interest rate | 1.23% | |||||||||||
Expected dividend rate | 0.00% | |||||||||||
Expected life | 5 years | |||||||||||
Fair value | $ 340,735 | |||||||||||
Beneficial conversion intrinsic value | 359,265 | |||||||||||
Debt discount | $ 700,000 | |||||||||||
Period for accretion of discount | P1Y3M | |||||||||||
February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member] | ||||||||||||
Interest expense | $ 7,724 | $ 18,548 | ||||||||||
Accretion of debt discount | 121,939 | $ 275,286 | ||||||||||
Debt discount | 168,000 | |||||||||||
Series F Warrant [Member] | February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member] | ||||||||||||
Debt instrument terms of conversion feature | (i) $3.45, the closing price of the Companys common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Companys common stock as quoted on the OTCQB for the five days prior to the date on which the holder elects to exercise the Warrant | |||||||||||
KCC [Member] | February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member] | ||||||||||||
Convertible debt financing, Maximum amount | $ 395,000 | $ 395,000 | ||||||||||
Interest rate | 7.00% | 7.00% | ||||||||||
KCC [Member] | Series F Warrant [Member] | February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member] | ||||||||||||
Common stock shares reserved under stock option plan | 114,493 | 114,493 | ||||||||||
KCC [Member] | Loan agreement [Member] | ||||||||||||
Interest expense | $ 13,051 | $ 38,093 | ||||||||||
Accretion of debt discount | 134,728 | 399,791 | ||||||||||
Convertible debt financing, Maximum amount | $ 900,000 | |||||||||||
Interest rate | 7.00% | |||||||||||
Maturity date | Dec. 31, 2017 | Feb. 23, 2018 | ||||||||||
Convertible debt financing, Loan received | $ 700,000 | $ 395,000 | 395,000 | 395,000 | ||||||||
Convertible debt financing, Remaining amount | $ 200,000 | |||||||||||
Debt instrument terms of conversion feature | (i) $1.54; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to convert the Note, subject to a floor price of $1.23. | (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76. | ||||||||||
Exercise Price | $ 1.25 | |||||||||||
Market price of common stock | $ 1.54 | |||||||||||
Estimated volatility | 92.30% | |||||||||||
Risk free interest rate | 1.23% | |||||||||||
Expected dividend rate | 0.00% | |||||||||||
Expected life | 5 years | |||||||||||
Fair value | $ 340,735 | |||||||||||
Beneficial conversion intrinsic value | 359,265 | |||||||||||
Debt discount | $ 700,000 | 134,728 | ||||||||||
Period for accretion of discount | 1.25 years | |||||||||||
KCC [Member] | Loan agreement [Member] | Series E Warrant [Member] | ||||||||||||
Common stock shares reserved under stock option plan | 584,416 | |||||||||||
Debt instrument terms of conversion feature | (i) $1.54; or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant. | |||||||||||
KCC [Member] | Loan agreement [Member] | Series F Warrant [Member] | ||||||||||||
Common stock shares reserved under stock option plan | 114,493 | |||||||||||
Debt instrument terms of conversion feature | (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant. | |||||||||||
Joseph Sierchio [Member] | February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member] | ||||||||||||
Convertible debt financing, Maximum amount | $ 25,000 | $ 25,000 | ||||||||||
Interest rate | 7.00% | 7.00% | ||||||||||
Maturity date | Feb. 23, 2018 | |||||||||||
Debt instrument terms of conversion feature | (i) $3.45, the closing price of the Companys common stock on the day prior to the issuance of the February 2017 Notes or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76 | |||||||||||
Joseph Sierchio [Member] | Series F Warrant [Member] | February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member] | ||||||||||||
Common stock shares reserved under stock option plan | 7,246 | 7,246 | ||||||||||
Joseph Sierchio [Member] | Loan agreement [Member] | ||||||||||||
Maturity date | Feb. 23, 2018 | |||||||||||
Convertible debt financing, Loan received | $ 25,000 | |||||||||||
Debt instrument terms of conversion feature | (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76. | |||||||||||
Joseph Sierchio [Member] | Loan agreement [Member] | Series F Warrant [Member] | ||||||||||||
Debt instrument terms of conversion feature | (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant. | |||||||||||
Investor [Member] | February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member] | ||||||||||||
Convertible debt financing, Maximum amount | $ 25,000 | $ 25,000 | ||||||||||
Interest rate | 7.00% | 7.00% | ||||||||||
Payments of notes payable | $ 25,000 | |||||||||||
Payments of accrued interest | $ 676 | |||||||||||
Investor [Member] | Series F Warrant [Member] | February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member] | ||||||||||||
Common stock shares reserved under stock option plan | 7,246 | 7,246 | ||||||||||
Debt instrument terms of conversion feature | (i) $3.45, the closing price of the Companys common stock on the day prior to issuance of the Series F Warrant; or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant |
Common Stock and Warrants (Deta
Common Stock and Warrants (Details) - $ / shares | 9 Months Ended | 12 Months Ended | ||||
Sep. 30, 2017 | Dec. 31, 2016 | Feb. 02, 2016 | Dec. 31, 2015 | Jun. 05, 2015 | Nov. 29, 2013 | |
Series A [Member] | ||||||
Shares of Common Stock Issuable from Warrants Outstanding | 720,000 | 960,000 | 960,000 | |||
Weighted Average Exercise Price | $ 0.35 | $ 0.35 | ||||
Expiration | Jul. 12, 2019 | Jul. 12, 2019 | ||||
Series B [Member] | ||||||
Shares of Common Stock Issuable from Warrants Outstanding | 1,326,087 | 3,500,000 | ||||
Weighted Average Exercise Price | $ 0.46 | $ 0.46 | $ 0.46 | $ 0.46 | ||
Expiration | Nov. 29, 2018 | Nov. 29, 2018 | ||||
Series C [Member] | ||||||
Shares of Common Stock Issuable from Warrants Outstanding | 3,500,000 | 3,500,000 | ||||
Weighted Average Exercise Price | $ 0.49 | $ 0.49 | $ 1.10 | $ 0.49 | ||
Expiration | Nov. 29, 2018 | Nov. 29, 2018 | ||||
Series D [Member] | ||||||
Shares of Common Stock Issuable from Warrants Outstanding | 910,000 | 910,000 | 1,010,000 | |||
Weighted Average Exercise Price | $ 1.10 | $ 1.10 | ||||
Expiration | Jun. 5, 2020 | Jun. 5, 2020 | ||||
Series E [Member] | ||||||
Shares of Common Stock Issuable from Warrants Outstanding | 584,416 | 584,416 | ||||
Weighted Average Exercise Price | $ 1.54 | $ 1.13 | ||||
Expiration | Sep. 8, 2021 | Sep. 8, 2021 | ||||
Series F Warrant [Member] | ||||||
Shares of Common Stock Issuable from Warrants Outstanding | 14,492 | |||||
Weighted Average Exercise Price | $ 3.45 | |||||
Expiration | Feb. 23, 2022 | |||||
Series G [Member] | ||||||
Shares of Common Stock Issuable from Warrants Outstanding | 460,250 | |||||
Weighted Average Exercise Price | $ 2.68 | |||||
Expiration | Jul. 21, 2022 | |||||
Warrant [Member] | ||||||
Shares of Common Stock Issuable from Warrants Outstanding | 2,689,158 | 7,280,503 | 8,970,000 | |||
Series F Warrant 1 [Member] | ||||||
Expiration | Mar. 9, 2022 |
Common Stock and Warrants (De36
Common Stock and Warrants (Details Narrative) - USD ($) | Mar. 01, 2017 | Feb. 10, 2017 | Jan. 10, 2017 | Dec. 06, 2016 | Sep. 09, 2016 | Feb. 02, 2016 | Aug. 05, 2015 | Jul. 21, 2017 | Jun. 28, 2017 | Feb. 17, 2017 | Sep. 30, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Jul. 12, 2018 | Jul. 12, 2017 | Jul. 12, 2016 | Jul. 12, 2015 | Jun. 05, 2015 | Jul. 12, 2014 | Nov. 29, 2013 |
Common stock, par value | $ 0.00001 | $ 0.00001 | $ 0.00001 | ||||||||||||||||||
Common stock, Authorized | 500,000,000 | 500,000,000 | 500,000,000 | ||||||||||||||||||
Common stock, shares Issued | 75,225,418 | 70,069,693 | 67,781,934 | ||||||||||||||||||
Common stock, shares outstanding | 75,225,418 | 70,069,693 | 67,781,934 | ||||||||||||||||||
Warrant exercised | 102,582 | ||||||||||||||||||||
Exercise Price | $ 1.25 | ||||||||||||||||||||
Estimated volatility | 92.30% | ||||||||||||||||||||
Market price of common stock | $ 1.54 | ||||||||||||||||||||
Risk free interest rate | 1.23% | ||||||||||||||||||||
Expected dividend rate | 0.00% | ||||||||||||||||||||
Expected life | 5 years | ||||||||||||||||||||
Common stock shares reserved under stock option plan | 102,582 | 19,595,000 | |||||||||||||||||||
Thomas bold [Member] | Equity Option [Member] | |||||||||||||||||||||
Warrant exercised | 40,000 | ||||||||||||||||||||
Issuance of common stock | 34,296 | ||||||||||||||||||||
Common stock shares reserved under stock option plan | 40,000 | ||||||||||||||||||||
Debt conversion converted insrtrument shares | 34,296 | ||||||||||||||||||||
Joseph Sierchio [Member] | Equity Option [Member] | |||||||||||||||||||||
Warrant exercised | 70,000 | ||||||||||||||||||||
Issuance of common stock | 38,642 | ||||||||||||||||||||
Common stock shares reserved under stock option plan | 70,000 | ||||||||||||||||||||
Debt conversion converted insrtrument shares | 38,642 | ||||||||||||||||||||
Series E [Member] | |||||||||||||||||||||
Warrant exercised | 584,416 | ||||||||||||||||||||
Weighted Average Exercise Price | $ 1.54 | $ 1.13 | |||||||||||||||||||
Maturity period | 5 years | ||||||||||||||||||||
Debt instrument conversion feature | (i) $1.54, the closing price of the Companys common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Companys common stock as quoted on the OTCQB for the five days prior to the date on which KCC elects to exercise the Warrant. | ||||||||||||||||||||
Common stock shares reserved under stock option plan | 584,416 | ||||||||||||||||||||
Series C [Member] | |||||||||||||||||||||
Warrant exercised | 3,500,000 | ||||||||||||||||||||
Weighted Average Exercise Price | 0.49 | 0.49 | $ 1.10 | $ 0.49 | |||||||||||||||||
Common stock shares reserved under stock option plan | 100,000 | 1,010,000 | 3,500,000 | ||||||||||||||||||
Common stock proceeds subscriptions | $ 110,000 | ||||||||||||||||||||
Series B [Member] | |||||||||||||||||||||
Warrant exercised | 3,500,000 | ||||||||||||||||||||
Issuance of common stock | 2,173,913 | ||||||||||||||||||||
Weighted Average Exercise Price | $ 0.46 | 0.46 | $ 0.46 | $ 0.46 | |||||||||||||||||
Proceeds from issuance of common stock | $ 1,000,000 | ||||||||||||||||||||
Common stock shares reserved under stock option plan | 2,173,913 | 3,500,000 | |||||||||||||||||||
Debt conversion converted insrtrument shares | 2,173,913 | ||||||||||||||||||||
Common stock proceeds subscriptions | $ 1,000,000 | $ 0 | |||||||||||||||||||
Series A [Member] | |||||||||||||||||||||
Weighted Average Exercise Price | 0.35 | $ 0.35 | |||||||||||||||||||
Series A [Member] | Dr. Gerlach [Member] | |||||||||||||||||||||
Common stock, shares Issued | 196,812 | ||||||||||||||||||||
Warrant exercised | 240,000 | 1,200,000 | |||||||||||||||||||
Issuance of common stock | 114,493 | 196,812 | |||||||||||||||||||
Weighted Average Exercise Price | $ 0.35 | ||||||||||||||||||||
Purchase number of shares | 240,000 | 240,000 | |||||||||||||||||||
Warrant vest five equal installments | 240,000 | 240,000 | 240,000 | 240,000 | 240,000 | ||||||||||||||||
Debt conversion converted insrtrument shares | 196,812 | ||||||||||||||||||||
Series D [Member] | |||||||||||||||||||||
Issuance of common stock | 100,000 | ||||||||||||||||||||
Weighted Average Exercise Price | 1.10 | $ 1.10 | |||||||||||||||||||
Proceeds from issuance of common stock | $ 110,001 | ||||||||||||||||||||
Debt conversion converted insrtrument shares | 100,000 | ||||||||||||||||||||
Common stock proceeds subscriptions | $ 110,001 | ||||||||||||||||||||
Series D [Member] | On June 5, 2015 [Member] | |||||||||||||||||||||
Warrant exercised | 1,010,000 | ||||||||||||||||||||
Weighted Average Exercise Price | $ 1.10 | ||||||||||||||||||||
Proceeds from issuance of common stock | $ 110,000 | ||||||||||||||||||||
Purchase and sale an aggregate shares | 1,010,000 | ||||||||||||||||||||
Debt conversion converted insrtrument shares | 1,010,000 | ||||||||||||||||||||
Joseph Sierchio [Member] | |||||||||||||||||||||
Warrant exercised | 20,000 | ||||||||||||||||||||
Issuance of common stock | 13,846 | ||||||||||||||||||||
Purchase number of shares | 20,000 | ||||||||||||||||||||
Debt conversion converted insrtrument shares | 13,846 | ||||||||||||||||||||
Series G [Member] | |||||||||||||||||||||
Weighted Average Exercise Price | 2.68 | ||||||||||||||||||||
Series F [Member] | KCC [Member] | |||||||||||||||||||||
Warrant exercised | 114,493 | ||||||||||||||||||||
Issuance of common stock | 114,493 | ||||||||||||||||||||
Weighted Average Exercise Price | $ 3.01 | ||||||||||||||||||||
Proceeds from issuance of common stock | $ 344,624 | ||||||||||||||||||||
Series C Warrant [Member] | KCC [Member] | |||||||||||||||||||||
Warrant exercised | 3,500,000 | ||||||||||||||||||||
Issuance of common stock | 3,092,637 | ||||||||||||||||||||
Series B Warrant [Member] | KCC [Member] | |||||||||||||||||||||
Warrant exercised | 1,326,087 | ||||||||||||||||||||
Issuance of common stock | 1,181,194 | ||||||||||||||||||||
Proceeds from issuance of common stock | $ 1,000,000 | ||||||||||||||||||||
Debt conversion converted insrtrument shares | 2,173,913 | ||||||||||||||||||||
Series B and C warrants [Member] | KCC [Member] | |||||||||||||||||||||
Issuance of common stock | 4,273,831 | ||||||||||||||||||||
Debt conversion converted insrtrument shares | 4,273,831 | ||||||||||||||||||||
Series A [Member] | Dr. Gerlach [Member] | |||||||||||||||||||||
Warrant exercised | 240,000 | ||||||||||||||||||||
Issuance of common stock | 204,571 | ||||||||||||||||||||
Common stock shares reserved under stock option plan | 240,000 | ||||||||||||||||||||
Debt conversion converted insrtrument shares | 204,571 | ||||||||||||||||||||
Series F Warrant [Member] | |||||||||||||||||||||
Weighted Average Exercise Price | $ 3.45 | ||||||||||||||||||||
Series F Warrant [Member] | KCC [Member] | |||||||||||||||||||||
Proceeds from issuance of common stock | $ 344,624 | ||||||||||||||||||||
Debt conversion converted insrtrument shares | 114,493 | ||||||||||||||||||||
Private Placement Member | KCC [Member] | |||||||||||||||||||||
Common stock shares reserved under stock option plan | 410,000 | ||||||||||||||||||||
Private Placement Member | Series G [Member] | |||||||||||||||||||||
Estimated volatility | 102.23% | ||||||||||||||||||||
Market price of common stock | $ 2.92 | ||||||||||||||||||||
Risk free interest rate | 1.81% | ||||||||||||||||||||
Expected dividend rate | 0.00% | ||||||||||||||||||||
Expected life | 5 years | ||||||||||||||||||||
Private Placement Member | Common Stock [Member] | |||||||||||||||||||||
Fair value of the common stock | $ 634,782 | ||||||||||||||||||||
2013 Plan [Member] | |||||||||||||||||||||
Warrant exercised | 19,338,572 | ||||||||||||||||||||
Self-directed offering [Member] | Private Placement Member | Series G [Member] | |||||||||||||||||||||
Maturity period | 5 years | ||||||||||||||||||||
Number of equity securities offered under the plan, shares | 460,250 | ||||||||||||||||||||
Share price | $ 2.44 | ||||||||||||||||||||
Number of equity securities offered under the plan, amount | $ 1,122,610 | ||||||||||||||||||||
Exercise Price | $ 2.68 | ||||||||||||||||||||
Fair value of the common stock | $ 487,828 | ||||||||||||||||||||
February 2017 Loan Agreements [Member] | Joseph Sierchio [Member] | From February 23, 2017 to March 9, 2017 [Member] | |||||||||||||||||||||
Debt instrument conversion feature | (i) $3.45, the closing price of the Companys common stock on the day prior to the issuance of the February 2017 Notes or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76 | ||||||||||||||||||||
February 2017 Loan Agreements [Member] | Series F Warrant [Member] | From February 23, 2017 to March 9, 2017 [Member] | |||||||||||||||||||||
Warrant exercised | 128,985 | ||||||||||||||||||||
Maturity period | 5 years | ||||||||||||||||||||
Warrants issued | 3 | ||||||||||||||||||||
Debt instrument conversion feature | (i) $3.45, the closing price of the Companys common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Companys common stock as quoted on the OTCQB for the five days prior to the date on which the holder elects to exercise the Warrant | ||||||||||||||||||||
February 2017 Loan Agreements [Member] | Series F Warrant [Member] | KCC [Member] | From February 23, 2017 to March 9, 2017 [Member] | |||||||||||||||||||||
Common stock shares reserved under stock option plan | 114,493 | ||||||||||||||||||||
February 2017 Loan Agreements [Member] | Series F Warrant [Member] | Joseph Sierchio [Member] | From February 23, 2017 to March 9, 2017 [Member] | |||||||||||||||||||||
Common stock shares reserved under stock option plan | 7,246 |
Stock Options (Details)
Stock Options (Details) - USD ($) | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016 | Dec. 31, 2015 | |
Number of Options | ||||
Options outstanding - beginning balance | 385,000 | 257,500 | 257,500 | 185,000 |
Options granted | 310,000 | 187,500 | 187,500 | 80,000 |
Options forfeited | (40,000) | (7,500) | ||
Options exercised | (150,000) | (20,000) | ||
Options oustanding - ending balance | 545,000 | 385,000 | 257,500 | |
Options exercisable | 375,000 | 347,500 | ||
Options available for grant | 19,338,572 | 19,595,000 | ||
Weighted average exercise price | ||||
Options outstanding - beginning balance | $ 1.42 | $ 1.07 | $ 1.07 | $ 0.83 |
Options granted | 4.20 | 1.92 | 1.54 | |
Options forfeited | 1.65 | 1.43 | ||
Options exercised | 1.12 | 0.80 | ||
Options outstanding - ending balance | 3.09 | 1.42 | $ 1.07 | |
Options exercisable | $ 2.75 | $ 1.44 | ||
Weighted average remaining contracted term | ||||
Options outstanding - ending balance | 8 years 10 months 10 days | 8 years 3 months 18 days | ||
Options exercisable | 8 years 8 months 9 days | 8 years 4 months 10 days | ||
Aggregate intrinsic value | ||||
Options outstanding - ending balance | $ 339,275 | $ 277,625 | ||
Options exercisable | $ 299,075 | $ 244,925 |
Stock Options (Details 1)
Stock Options (Details 1) | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Expected life in years | 5 years 6 months | 5 years | |
Weighted Avg. Expected Volatility | 92.30% | ||
Expected dividend yield | 0.00% | 0.00% | 0.00% |
Minimum [Member] | |||
Risk-free interest rate | 1.93% | 1.23% | 1.49% |
Expected life in years | 5 years 6 months | ||
Weighted Avg. Expected Volatility | 98.00% | 88.40% | |
Maximum [Member] | |||
Risk-free interest rate | 2.39% | 1.41% | 1.70% |
Expected life in years | 10 years | ||
Weighted Avg. Expected Volatility | 106.00% | 105.30% |
Stock Options (Details 2)
Stock Options (Details 2) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Stock Options Details 2 | ||||
Research and development | $ 10,725 | $ 75,515 | ||
General and administrative | 116,753 | 12,951 | 672,835 | 287,238 |
Total | $ 127,478 | $ 12,951 | $ 748,350 | $ 287,238 |
Stock Options (Details 3)
Stock Options (Details 3) - $ / shares | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Number of Stock Options Outstanding | 545,000 | 385,000 |
Options Outstanding, Weighted Average Contractual Life (years) | 8 years 10 months 10 days | 8 years 3 months 18 days |
Options Outstanding, Weighted Average Exercise Price | $ 3.09 | $ 1.42 |
Number of Stock Options Exercisable | 375,000 | 347,500 |
Options Exercisable, Weighted Average Remaining Contractual Life (Years) | 8 years 8 months 9 days | 8 years 4 months 10 days |
Options Exercisable, Weighted Average Exercise Price | $ 2.75 | $ 1.44 |
Exercise Price Range One [Member] | ||
Range of Exercise Prices | $ 0.80 | $ 0.65 |
Number of Stock Options Outstanding | 10,000 | 40,000 |
Options Outstanding, Weighted Average Contractual Life (years) | 6 years 10 months 14 days | 7 years 4 days |
Options Outstanding, Weighted Average Exercise Price | $ 0.80 | $ 0.65 |
Number of Stock Options Exercisable | 10,000 | 40,000 |
Options Exercisable, Weighted Average Remaining Contractual Life (Years) | 6 years 10 months 14 days | 7 years 4 days |
Options Exercisable, Weighted Average Exercise Price | $ 0.80 | $ 0.65 |
Exercise Price Range Two [Member] | ||
Range of Exercise Prices | $ 1.05 | $ 0.75 |
Number of Stock Options Outstanding | 55,000 | 40,000 |
Options Outstanding, Weighted Average Contractual Life (years) | 6 years 6 months | 6 years 11 months 1 day |
Options Outstanding, Weighted Average Exercise Price | $ 1.05 | $ 0.75 |
Number of Stock Options Exercisable | 35,000 | 40,000 |
Options Exercisable, Weighted Average Remaining Contractual Life (Years) | 6 years 6 months | 6 years 11 months 1 day |
Options Exercisable, Weighted Average Exercise Price | $ 1.05 | $ 0.75 |
Exercise Price Range Three [Member] | ||
Range of Exercise Prices | $ 1.25 | $ 0.8 |
Number of Stock Options Outstanding | 7,500 | 30,000 |
Options Outstanding, Weighted Average Contractual Life (years) | 7 years 8 months 16 days | 7 years 7 months 13 days |
Options Outstanding, Weighted Average Exercise Price | $ 1.25 | $ 0.8 |
Number of Stock Options Exercisable | 7,500 | 30,000 |
Options Exercisable, Weighted Average Remaining Contractual Life (Years) | 7 years 8 months 16 days | 7 years 7 months 13 days |
Options Exercisable, Weighted Average Exercise Price | $ 1.25 | $ 0.8 |
Exercise Price Range Four [Member] | ||
Range of Exercise Prices | $ 1.34 | $ 1.05 |
Number of Stock Options Outstanding | 7,500 | 55,000 |
Options Outstanding, Weighted Average Contractual Life (years) | 7 years 9 months | 7 years 3 months |
Options Outstanding, Weighted Average Exercise Price | $ 1.34 | $ 1.05 |
Number of Stock Options Exercisable | 7,500 | 25,000 |
Options Exercisable, Weighted Average Remaining Contractual Life (Years) | 7 years 9 months | 7 years 3 months |
Options Exercisable, Weighted Average Exercise Price | $ 1.34 | $ 1.05 |
Exercise Price Range Five [Member] | ||
Range of Exercise Prices | $ 1.65 | $ 1.25 |
Number of Stock Options Outstanding | 10,000 | 7,500 |
Options Outstanding, Weighted Average Contractual Life (years) | 8 years 1 month 2 days | 8 years 5 months 16 days |
Options Outstanding, Weighted Average Exercise Price | $ 1.65 | $ 1.25 |
Number of Stock Options Exercisable | 10,000 | 7,500 |
Options Exercisable, Weighted Average Remaining Contractual Life (Years) | 8 years 1 month 2 days | 8 years 5 months 16 days |
Options Exercisable, Weighted Average Exercise Price | $ 1.65 | $ 1.25 |
Exercise Price Range Six [Member] | ||
Range of Exercise Prices | $ 1.70 | $ 1.34 |
Number of Stock Options Outstanding | 7,500 | 7,500 |
Options Outstanding, Weighted Average Contractual Life (years) | 8 years 15 days | 8 years 6 months |
Options Outstanding, Weighted Average Exercise Price | $ 1.70 | $ 1.34 |
Number of Stock Options Exercisable | 7,500 | 7,500 |
Options Exercisable, Weighted Average Remaining Contractual Life (Years) | 8 years 15 days | 8 years 6 months |
Options Exercisable, Weighted Average Exercise Price | $ 1.70 | $ 1.34 |
Exercise Price Range Seven [Member] | ||
Range of Exercise Prices | $ 1.91 | $ 1.65 |
Number of Stock Options Outstanding | 130,000 | 10,000 |
Options Outstanding, Weighted Average Contractual Life (years) | 8 years 5 months 16 days | 8 years 10 months 2 days |
Options Outstanding, Weighted Average Exercise Price | $ 1.91 | $ 1.65 |
Number of Stock Options Exercisable | 130,000 | 10,000 |
Options Exercisable, Weighted Average Remaining Contractual Life (Years) | 8 years 5 months 16 days | 8 years 10 months 2 days |
Options Exercisable, Weighted Average Exercise Price | $ 1.91 | $ 1.65 |
Exercise Price Range Eight [Member] | ||
Range of Exercise Prices | $ 2.28 | $ 1.7 |
Number of Stock Options Outstanding | 7,500 | 7,500 |
Options Outstanding, Weighted Average Contractual Life (years) | 8 years 9 months 22 days | 8 years 9 months 15 days |
Options Outstanding, Weighted Average Exercise Price | $ 2.28 | $ 1.7 |
Number of Stock Options Exercisable | 7,500 | 7,500 |
Options Exercisable, Weighted Average Remaining Contractual Life (Years) | 8 years 9 months 22 days | 8 years 9 months 15 days |
Options Exercisable, Weighted Average Exercise Price | $ 2.28 | $ 1.7 |
Exercise Price Range Nine [Member] | ||
Range of Exercise Prices | $ 4.20 | $ 1.91 |
Number of Stock Options Outstanding | 310,000 | 180,000 |
Options Outstanding, Weighted Average Contractual Life (years) | 9 years 7 months 13 days | 9 years 2 months 16 days |
Options Outstanding, Weighted Average Exercise Price | $ 4.20 | $ 1.91 |
Number of Stock Options Exercisable | 160,000 | 180,000 |
Options Exercisable, Weighted Average Remaining Contractual Life (Years) | 9 years 7 months 13 days | 9 years 2 months 16 days |
Options Exercisable, Weighted Average Exercise Price | $ 4.20 | $ 1.91 |
Exercise Price Range Ten [Member] | ||
Range of Exercise Prices | $ 2.28 | |
Number of Stock Options Outstanding | 7,500 | |
Options Outstanding, Weighted Average Contractual Life (years) | 9 years 6 months 22 days | |
Options Outstanding, Weighted Average Exercise Price | $ 2.28 | |
Number of Stock Options Exercisable | ||
Options Exercisable, Weighted Average Remaining Contractual Life (Years) | 9 years 6 months 22 days | |
Options Exercisable, Weighted Average Exercise Price | $ 2.28 |
Stock Options (Details Narrativ
Stock Options (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | 11 Months Ended | 12 Months Ended | |||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | May 11, 2018 | Dec. 31, 2016 | Dec. 31, 2015 | |
Common stock shares reserved under stock option plan | 102,582 | 102,582 | 19,595,000 | ||||
Available shares for granted | 19,338,572 | 19,338,572 | |||||
Options granted | 310,000 | 187,500 | 187,500 | 80,000 | |||
Weighted-average grant date fair value | $ 3.38 | $ 1.41 | $ 37,500 | $ 1.18 | |||
Options excercised | (150,000) | (20,000) | |||||
Aggregate intrinsic value | $ 397,100 | $ 36,000 | |||||
Stock based compensation expense | $ 127,478 | $ 12,951 | $ 748,350 | $ 287,238 | 282,262 | $ 59,122 | |
Unrecognized compensation cost | $ 8,404 | ||||||
Unrecognized compensation cost expected life | 2 years 3 months | ||||||
2013 Plan [Member] | |||||||
Common stock shares reserved under stock option plan | 20,000,000 | ||||||
Stock options grant description | No person may be granted in any of the Company's fiscal year, options to purchase more than 2,000,000 shares under the 2013 Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the 2013 Plan are exercisable no later than ten years after the date of grant. | ||||||
Excecise price per share limit | Not be less than 110% of the fair market value | ||||||
Option granted before date | Jun. 20, 2023 | ||||||
Stock options incentive percentage description | ten percent or more |
Commitments (Details Narrative)
Commitments (Details Narrative) - USD ($) | Mar. 01, 2017 | Mar. 01, 2015 | Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016 | Dec. 31, 2015 | May 01, 2016 | Aug. 01, 2013 |
Consulting Agreement [Member] | ||||||||||
Consulting fees in consideration of the services | $ 6,800 | $ 5,000 | ||||||||
Pittsburgh Life Sciences Greenhouse [Member] | ||||||||||
Monthly rent | $ 800 | $ 750 | ||||||||
Lease termination description | The Company has the option to terminate the Lease on the twelve month anniversary of the commencement date, upon one hundred and twenty days prior written notice. | |||||||||
StemCell Systems [Member] | ||||||||||
Incurred expenses | $ 39,708 | $ 24,000 | $ 146,538 | $ 134,567 | $ 184,517 | $ 194,336 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Deferred tax assets: | ||
Net operating loss carryforwards | $ 3,217,000 | $ 2,646,000 |
Intangible asset | 158,000 | 84,000 |
Capital loss carryforward | 236,000 | |
Stock-based compensation | 139,000 | 46,000 |
Deferred tax assets gross | 3,750,000 | 2,776,000 |
Valuation allowance | (3,750,000) | (2,776,000) |
Net deferred tax assets |
Income Taxes (Details 1)
Income Taxes (Details 1) | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Income Taxes Details 1 | ||
Statutory federal income tax rate | 34.00% | 34.00% |
Permanent differences and other | 13.00% | (22.00%) |
Valuation allowance | (47.00%) | (12.00%) |
Income tax provision (benefit) | 0.00% | 0.00% |
Income Taxes (Details Narrative
Income Taxes (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Income Taxes Details Narrative | ||
Statutory federal income tax rate | 34.00% | 34.00% |
Increase in the valuation allowance | $ 974,000 | $ 154,000 |
Net operating loss and contribution carryforwards | $ 9,302,000 | |
Net operating loss and contribution carryforwards expiry | 2018 through to the year 2036 | |
Capital loss carryforward expiration period | During 2,018 |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) | May 11, 2017$ / sharesshares | Mar. 01, 2017shares | Feb. 10, 2017shares | Jan. 10, 2017shares | Sep. 09, 2016USD ($)$ / sharesshares | Mar. 15, 2016$ / sharesshares | Feb. 02, 2016USD ($)$ / sharesshares | May 01, 2015USD ($)Installment | Jul. 21, 2017USD ($)$ / sharesshares | Jun. 28, 2017USD ($)$ / sharesshares | Mar. 01, 2017shares | Feb. 28, 2017 | Feb. 28, 2017 | Feb. 23, 2017USD ($) | Feb. 17, 2017shares | Sep. 25, 2014USD ($)Installment | Sep. 30, 2017USD ($)$ / sharesshares | Sep. 30, 2016USD ($) | Sep. 30, 2017USD ($)$ / sharesshares | Sep. 30, 2016USD ($)$ / shares | May 11, 2018$ / shares | Dec. 31, 2016USD ($)$ / sharesshares | Dec. 31, 2015USD ($) | Feb. 27, 2017shares | Nov. 01, 2015USD ($) |
Common stock shares reserved under stock option plan | shares | 102,582 | 102,582 | 19,595,000 | ||||||||||||||||||||||
Stock option grant vested | $ / shares | $ 3.38 | $ 1.41 | $ 37,500 | $ 1.18 | |||||||||||||||||||||
Accounts payable | $ 20,000 | $ 20,000 | $ 33,290 | $ 30,095 | |||||||||||||||||||||
Research and development expense | $ 139,819 | $ 45,381 | $ 363,785 | $ 231,013 | $ 309,503 | 281,218 | |||||||||||||||||||
Exercise Price | $ / shares | $ 3.09 | $ 3.09 | $ 1.42 | ||||||||||||||||||||||
Charitable Grant Agreement [Member] | |||||||||||||||||||||||||
Donation to the University | $ 75,000 | ||||||||||||||||||||||||
Donation periodic payment | $ 9,375 | ||||||||||||||||||||||||
Number of installments | Installment | 8 | ||||||||||||||||||||||||
Charitable Gift Agreement [Member] | |||||||||||||||||||||||||
Donation to the University | $ 83,000 | ||||||||||||||||||||||||
Dr. Gerlach [Member] | |||||||||||||||||||||||||
Compensation expense for services | $ 10,000 | 9,200 | $ 28,540 | 33,210 | $ 42,480 | 36,720 | |||||||||||||||||||
Accounts payable | 10,000 | 10,000 | 18,540 | ||||||||||||||||||||||
Joseph Sierchio [Member] | |||||||||||||||||||||||||
Annual retainer payable | 6,000 | $ 6,000 | $ 6,000 | ||||||||||||||||||||||
Common stock shares reserved under stock option plan | shares | 75,000 | 50,000 | 50,000 | ||||||||||||||||||||||
Exercise price | $ / shares | $ 4.20 | $ 1.91 | $ 1.91 | ||||||||||||||||||||||
Legal fees | 15,115 | 30,080 | $ 195,783 | 121,595 | $ 168,775 | 101,700 | |||||||||||||||||||
Accounts payable | 10,000 | 10,000 | 11,750 | 8,322 | |||||||||||||||||||||
Kenneth Kirkland [Member] | |||||||||||||||||||||||||
Annual retainer payable | 6,000 | 6,000 | $ 6,000 | ||||||||||||||||||||||
Common stock shares reserved under stock option plan | shares | 75,000 | 50,000 | 50,000 | ||||||||||||||||||||||
Exercise price | $ / shares | $ 4.20 | $ 1.91 | $ 1.91 | ||||||||||||||||||||||
Option agreement [Member] | Dr. Gerlach [Member] | |||||||||||||||||||||||||
Number of installments | Installment | 4 | ||||||||||||||||||||||||
Fees payable under agreement | $ 24,000 | ||||||||||||||||||||||||
Due to related party periodic payment | 6,000 | ||||||||||||||||||||||||
Research and development expense | $ 24,000 | ||||||||||||||||||||||||
Series A [Member] | Dr. Gerlach [Member] | |||||||||||||||||||||||||
Common stock shares reserved under stock option plan | shares | 240,000 | ||||||||||||||||||||||||
Debt conversion converted instrument shares issued | shares | 204,571 | ||||||||||||||||||||||||
KCC [Member] | Loan agreement [Member] | |||||||||||||||||||||||||
Convertible debt financing, Maximum amount | $ 900,000 | ||||||||||||||||||||||||
Convertible debt financing, Loan received | 700,000 | $ 395,000 | 395,000 | 395,000 | |||||||||||||||||||||
Convertible debt financing, Remaining amount | $ 200,000 | ||||||||||||||||||||||||
Interest rate | 7.00% | ||||||||||||||||||||||||
Maturity date | Dec. 31, 2017 | Feb. 23, 2018 | |||||||||||||||||||||||
Debt instrument conversion feature | (i) $1.54; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to convert the Note, subject to a floor price of $1.23. | (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76. | |||||||||||||||||||||||
Debt instrument floor price | $ / shares | $ 1.23 | ||||||||||||||||||||||||
KCC [Member] | Series B and C warrants [Member] | |||||||||||||||||||||||||
Debt conversion converted instrument shares issued | shares | 4,273,831 | ||||||||||||||||||||||||
KCC [Member] | Series C Warrant [Member] | |||||||||||||||||||||||||
Number of warrants exercised | shares | 3,092,637 | ||||||||||||||||||||||||
KCC [Member] | Series B Warrant [Member] | |||||||||||||||||||||||||
Number of warrants exercised | shares | 1,326,087 | ||||||||||||||||||||||||
Debt conversion converted instrument shares issued | shares | 2,173,913 | ||||||||||||||||||||||||
Exercise Price | $ / shares | $ 0.46 | ||||||||||||||||||||||||
Proceeds from issuance of common stock | $ 1,000,000 | ||||||||||||||||||||||||
KCC [Member] | Series F Warrant [Member] | |||||||||||||||||||||||||
Number of warrants exercised | shares | 114,493 | ||||||||||||||||||||||||
Debt conversion converted instrument shares issued | shares | 114,493 | ||||||||||||||||||||||||
Exercise Price | $ / shares | $ 3.01 | ||||||||||||||||||||||||
Proceeds from issuance of common stock | $ 344,624 | ||||||||||||||||||||||||
KCC [Member] | Series F Warrant [Member] | Loan agreement [Member] | |||||||||||||||||||||||||
Common stock shares reserved under stock option plan | shares | 114,493 | ||||||||||||||||||||||||
Debt instrument conversion feature | (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant. | ||||||||||||||||||||||||
Warrant expiration period | 5 years | ||||||||||||||||||||||||
KCC [Member] | Series E Warrant [Member] | Loan agreement [Member] | |||||||||||||||||||||||||
Common stock shares reserved under stock option plan | shares | 584,416 | ||||||||||||||||||||||||
Debt instrument conversion feature | (i) $1.54; or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant. | ||||||||||||||||||||||||
Warrant expiration period | 5 years | ||||||||||||||||||||||||
KCC [Member] | Private Placement Member | |||||||||||||||||||||||||
Common stock shares reserved under stock option plan | shares | 410,000 | ||||||||||||||||||||||||
Unit price per share | $ / shares | $ 2.44 | ||||||||||||||||||||||||
Proceeds from units reserved for future issuance | $ 1,000,400 | ||||||||||||||||||||||||
Terms of agreement | Each unit consisted of one share of common stock and one Series G Warrant to purchase one (1) share of common stock at an exercise price of $2.68 per share through July 21, 2022. The warrants may be exercised on a cashless basis | ||||||||||||||||||||||||
KCC [Member] | Private Placement Member | Series G [Member] | |||||||||||||||||||||||||
Exercise price | $ / shares | $ 2.68 | ||||||||||||||||||||||||
Joseph Sierchio [Member] | Loan agreement [Member] | |||||||||||||||||||||||||
Convertible debt financing, Loan received | $ 25,000 | ||||||||||||||||||||||||
Maturity date | Feb. 23, 2018 | ||||||||||||||||||||||||
Debt instrument conversion feature | (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76. | ||||||||||||||||||||||||
Joseph Sierchio [Member] | Equity Option [Member] | |||||||||||||||||||||||||
Common stock shares reserved under stock option plan | shares | 70,000 | ||||||||||||||||||||||||
Debt conversion converted instrument shares issued | shares | 38,642 | ||||||||||||||||||||||||
Joseph Sierchio [Member] | Series F Warrant [Member] | Loan agreement [Member] | |||||||||||||||||||||||||
Debt instrument conversion feature | (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant. | ||||||||||||||||||||||||
Warrant expiration period | 5 years | ||||||||||||||||||||||||
Thomas bold [Member] | Equity Option [Member] | |||||||||||||||||||||||||
Common stock shares reserved under stock option plan | shares | 40,000 | ||||||||||||||||||||||||
Debt conversion converted instrument shares issued | shares | 34,296 | ||||||||||||||||||||||||
Satterlee Stephens LLP [Member] | |||||||||||||||||||||||||
Accounts payable | $ 11,750 | ||||||||||||||||||||||||
StemCell Systems [Member] | |||||||||||||||||||||||||
Incurred expenses | $ 39,708 | $ 24,000 | $ 146,538 | $ 134,567 | $ 184,517 | $ 194,336 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) | Mar. 09, 2017USD ($)$ / sharesshares | Mar. 02, 2017shares | Feb. 10, 2017shares | Jan. 10, 2017shares | Feb. 02, 2016shares | Oct. 16, 2017USD ($)$ / sharesshares | Jun. 28, 2017shares | Mar. 02, 2017shares | Feb. 23, 2017USD ($)$ / sharesshares | Feb. 17, 2017shares | Mar. 23, 2017Installment | Mar. 09, 2017USD ($)$ / sharesshares | Sep. 30, 2017shares | May 11, 2017shares | Feb. 02, 2017shares | Dec. 31, 2016shares | Mar. 15, 2016shares |
Common stock shares reserved under stock option plan | 102,582 | 19,595,000 | |||||||||||||||
Series F Warrant [Member] | KCC [Member] | |||||||||||||||||
Common stock shares issued upon conversion of debt | 114,493 | ||||||||||||||||
Series B Warrant [Member] | KCC [Member] | |||||||||||||||||
Common stock shares issued upon conversion of debt | 2,173,913 | ||||||||||||||||
Kenneth Kirkland [Member] | |||||||||||||||||
Common stock shares reserved under stock option plan | 75,000 | 50,000 | 50,000 | ||||||||||||||
Subsequent Event [Member] | Self-directed offering [Member] | |||||||||||||||||
Number of equity securities offered under the plan, shares | 920,000 | ||||||||||||||||
Share price | $ / shares | $ 2.50 | ||||||||||||||||
Number of equity securities offered under the plan, amount | $ | $ 2,300,000 | ||||||||||||||||
Class of warrants or rights issued, description | Each purchaser received one stock purchase warrant for each share of stock purchased for no additional consideration. Each warrant is exercisable at a price of $2.75 per share for a period of five years | ||||||||||||||||
Subsequent Event [Member] | Equity Option [Member] | |||||||||||||||||
Common stock shares reserved under stock option plan | 40,000 | ||||||||||||||||
Common stock shares issued upon conversion of debt | 34,296 | ||||||||||||||||
Subsequent Event [Member] | Series C Warrant [Member] | KCC [Member] | |||||||||||||||||
Common stock shares reserved under stock option plan | 3,500,000 | 3,500,000 | |||||||||||||||
Common stock shares issued upon conversion of debt | 3,092,637 | ||||||||||||||||
Subsequent Event [Member] | Series B Warrant [Member] | KCC [Member] | |||||||||||||||||
Common stock shares reserved under stock option plan | 1,326,087 | 1,326,087 | |||||||||||||||
Common stock shares issued upon conversion of debt | 1,181,194 | ||||||||||||||||
Subsequent Event [Member] | February 2017 Loan Agreements [Member] | |||||||||||||||||
Number of loan agreements | Installment | 2 | ||||||||||||||||
Subsequent Event [Member] | February 2017 Loan Agreements [Member] | KCC [Member] | |||||||||||||||||
Convertible debt financing, principal amount | $ | $ 395,000 | ||||||||||||||||
Maturity date | Feb. 23, 2018 | ||||||||||||||||
Debt instrument conversion feature | (i) $3.45, the closing price of the Companys common stock on the day prior to the issuance of the February 2017 Notes or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76 | ||||||||||||||||
Debt instrument floor price | $ / shares | $ 2.76 | ||||||||||||||||
Subsequent Event [Member] | February 2017 Loan Agreements [Member] | Joseph Sierchio [Member] | |||||||||||||||||
Convertible debt financing, principal amount | $ | $ 25,000 | ||||||||||||||||
Maturity date | Feb. 23, 2018 | ||||||||||||||||
Debt instrument conversion feature | (i) $3.45, the closing price of the Companys common stock on the day prior to the issuance of the February 2017 Notes or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76 | ||||||||||||||||
Debt instrument floor price | $ / shares | $ 2.76 | ||||||||||||||||
Subsequent Event [Member] | February 2017 Loan Agreements [Member] | Series F Warrant [Member] | KCC [Member] | |||||||||||||||||
Common stock shares reserved under stock option plan | 114,193 | ||||||||||||||||
Debt instrument conversion feature | (i) $3.45, the closing price of the Companys common stock on the day prior to issuance of the Series F Warrant; or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant | ||||||||||||||||
Subsequent Event [Member] | February 2017 Loan Agreements [Member] | Series F Warrant [Member] | Joseph Sierchio [Member] | |||||||||||||||||
Common stock shares reserved under stock option plan | 7,246 | ||||||||||||||||
Debt instrument conversion feature | (i) $3.45, the closing price of the Companys common stock on the day prior to issuance of the Series F Warrant; or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant | ||||||||||||||||
Subsequent Event [Member] | Investor [Member] | March 2017 loan agreements [Member] | |||||||||||||||||
Convertible debt financing, principal amount | $ | $ 25,000 | $ 25,000 | |||||||||||||||
Maturity date | Feb. 23, 2018 | ||||||||||||||||
Debt instrument conversion feature | (i) $3.45, or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which the Investor elects to convert the March 2017 Note, subject to a floor price of $2.76 | ||||||||||||||||
Debt instrument floor price | $ / shares | $ 2.76 | $ 2.76 | |||||||||||||||
Subsequent Event [Member] | Investor [Member] | March 2017 loan agreements [Member] | Series F Warrant [Member] | |||||||||||||||||
Common stock shares reserved under stock option plan | 7,246 | 7,246 | |||||||||||||||
Debt instrument conversion feature | (i) $3.45, or (ii) a 20% discount to the average closing price of the Companys common stock for the five days prior to the date on which the Investor elects to exercise their Series F Warrant | ||||||||||||||||
Warrant expiration period | 5 years | ||||||||||||||||
Subsequent Event [Member] | Board of directors [Member] | Equity Option [Member] | |||||||||||||||||
Common stock shares reserved under stock option plan | 70,000 | ||||||||||||||||
Common stock shares issued upon conversion of debt | 38,642 | ||||||||||||||||
Subsequent Event [Member] | Kenneth Kirkland [Member] | Equity Option [Member] | |||||||||||||||||
Common stock shares reserved under stock option plan | 40,000 | ||||||||||||||||
Common stock shares issued upon conversion of debt | 29,642 | ||||||||||||||||
Subsequent Event [Member] | Dr. Gerlach [Member] | Warrant [Member] | |||||||||||||||||
Common stock shares reserved under stock option plan | 240,000 | ||||||||||||||||
Common stock shares issued upon conversion of debt | 204,571 |